

6370 Wilcox Road Dublin, Ohio 43016

Telephone: 614-889-1061

August 18, 2009

Department of Administration Purchasing Division Building 15 2019 Washington Street, East Charleston, WV 25305-0130

Dear Purchasing Department:

As you may know, LabCorp is one of the largest and most innovative laboratory organizations in the country, capable of meeting the needs of virtually any provider. Our success was fostered by one primary objective: Provide a clinical laboratory services program that is responsive to clients' needs, wants and expectations. Our business strategy allows us to meet and anticipate the changing needs of our clients and prospects alike.

Convenience, quality, a comprehensive portfolio and excellent service describe LabCorp's network of strategically located patient service centers, local laboratories, a national esoteric laboratory and our Centers for Excellence. This network provides you with the individual attention and dependability of local personnel coupled with the support and strength of a national organization dedicated to researching, developing and implementing leading edge health care technology.

Attached for your examination is the LabCorp response to the July 22, 2009, RFQ BHS10009. Once you have reviewed this information, I hope that you will conclude that LabCorp is committed to and capable of providing you with the finest laboratory testing service available. Thank you for this opportunity to introduce LabCorp's advantages.

Sincerely,

L. Edward Gullett, Jr.

Vice President, Controller



VENDOR

DUBLIN OH

State of West Virginia Department of Administration Purchasing Division 2019 Washington Street East Post Office Box 50130 Charleston, WV 25305-0130

Request for Quotation

RFQ NUMBER BHS10009

ADDRESS CORRESPONDENCE TO ATTENTION OF:

HEALTH AND HUMAN RESOURCES

ROBERTA WAGNER 804-558-0067

*713133556 800-282-7300 LABORATORY CORPORATION OF AMER 6370 WILCOX ROAD

43016-1296

BBH/HF **ROOM 350**

350 CAPITOL STREET CHARLESTON, WV

25301-3702

304-558-3672

| DATE PRI | TEF TEF | RMS OF SALE | SHIP VIA | F.O.B. | FREIGHT TERMS |
|------------------|--|---|---|--------------------------------------|---------------------------|
| 07/22 | ·- · | | | | |
| BID OPENING DATE | 08/26/ | | BID | OPENING TIME 01 | ·30PM |
| LINE | QUANTITY | UOP CAT NO. | ITEM NUMBER | UNIT PRICE | AMOUNT |
| 0001 | 1 OPEN END CON | YR TRACT FOR | 193-88 REFERENCE LABORA | TORY SERVICES | |
| | THE WEST VIR RESOURCES ST WILLIAM R MILDRED M PINECREST LAKIN HOS WELCH COM HOPEMONT | GINIA DEPA ATE-OWNED SHARPE, J ITCHELL BA HOSPITAL PITAL MUNITY HOS HOSPITAL HIN SR. HE | ALTH CARE CENTER | AND HUMAN | |
| | r - | WRITING N | HE SPECIFICATION: O LATER THAT 4:30 | S MUST BE OPM ON 7/31/09 TO | |
| | 2019 WA CHARLES' FAX: 3 | ING DIVISI SHINGTON S TON, WV 2 04-558-411 | TREET, EAST 5305 | • | A 10: 19 HADIVISION OF WV |
| | EXHIBIT 3 | | | SIAIR | CE MA |
| | | AN. SUCH "RE | IS CONTRACT BECOME DEXTENDS FOR A PAISONABLE TIME" THE NEW CONTRACT OR PAISONABLE | PERIOD OF ONE (1) HEREAFTER AS IS | |
| SIGNATURE 4 | A | SEE RE | VERSE SIDE FOR TERMS AND CO | | |
| SIGNATURE E | went In | | TELEPHONE 61 | L4-889-1061 | 8/20/09 |
| Vice Presid | lent Controlle | 13-37573 | | | TO BE NOTED ABOVE |
| | | | | IN ODAGE ABOVE LABELE | |

GENERAL TERMS & CONDITIONS REQUEST FOR QUOTATION (RFQ) AND REQUEST FOR PROPOSAL (RFP)

- 1. Awards will be made in the best interest of the State of West Virginia.
- 2. The State may accept or reject in part, or in whole, any bid
- 3. All quotations are governed by the West Virginia Code and the Legislative Rules of the Purchasing Division.
- 4. Prior to any award, the apparent successful vendor must be properly registered with the Purchasing Division and have paid the required \$125 fee
- 5. All services performed or goods delivered under State Purchase Order/Contracts are to be continued for the term of the Purchase Order/Contracts, contingent upon funds being appropriated by the Legislature or otherwise being made available. In the event funds are not appropriated or otherwise available for these services or goods, this Purchase Order/Contract becomes void and of no effect after June 30.
- 6. Payment may only be made after the delivery and acceptance of goods or services.
- 7. Interest may be paid for late payment in accordance with the West Virginia Code.
- 8. Vendor preference will be granted upon written request in accordance with the West Virginia Code.
- 9. The State of West Virginia is exempt from federal and state taxes and will not pay or reimburse such taxes
- 10. The Director of Purchasing may cancel any Purchase Order/Contract upon 30 days written notice to the seller
- 11. The laws of the State of West Virginia and the *Legislative Rules* of the Purchasing Division shall govern all rights and duties under the Contract, including without limitation the validity of this Purchase Order/Contract.
- 12. Any reference to automatic renewal is hereby deleted. The Contract may be renewed only upon mutual written agreement of the parties.
- 13. BANKRUPTCY: In the event the vendor/contractor files for bankruptcy protection, the State may deem this contract null and void, and terminate such contract without further order.
- 14. HIPAA BUSINESS ASSOCIATE ADDENDUM: The West Virginia State Government HIPAA Business Associate Addendum (BAA), approved by the Attorney General, and available online at the Purchasing Division's web site (http://www.state.wv.us/admin/purchase/vrc/hipaa.htm) is hereby made part of the agreement. Provided that, the Agency meets the definition of a Cover Entity (45 CFR §160.103) and will be disclosing Protected Health Information (45 CFR §160.103) to the vendor.
- 15. WEST VIRGINIA ALCOHOL & DRUG-FREE WORKPLACE ACT: If this Contract constitutes a public improvement construction contract as set forth in Article 1D, Chapter 21 of the West Virginia Code ("The West Virginia Alcohol and Drug-Free Workplace Act"), then the following language shall hereby become part of this Contract: "The contractor and its subcontractors shall implement and maintain a written drug-free workplace policy in compliance with the West Virginia Alcohol and Drug-Free Workplace Act, as set forth in Article 1D, Chapter 21 of the West Virginia Code. The contractor and its subcontractors shall provide a sworn statement in writing, under the penalties of perjury, that they maintain a valid drug-free work place policy in compliance with the West Virginia and Drug-Free Workplace Act. It is understood and agreed that this Contract shall be cancelled by the awarding authority if the Contractor: 1) Fails to implement its drug-free workplace policy; 2) Fails to provide information regarding implementation of the contractor's drug-free workplace policy at the request of the public authority; or 3) Provides to the public authority false information regarding the contractor's drug-free workplace policy."

INSTRUCTIONS TO BIDDERS

- 1. Use the quotation forms provided by the Purchasing Division.
- 2. SPECIFICATIONS: Items offered must be in compliance with the specifications. Any deviation from the specifications must be clearly indicated by the bidder. Alternates offered by the bidder as EQUAL to the specifications must be clearly defined. A bidder offering an alternate should attach complete specifications and literature to the bid. The Purchasing Division may waive minor deviations to specifications.
- Complete all sections of the quotation form.
- 4. Unit prices shall prevail in case of discrepancy.
- 5. All quotations are considered F.O.B. destination unless alternate shipping terms are clearly identified in the quotation.
- **6. BID SUBMISSION:** All quotations must be delivered by the bidder to the office listed below prior to the date and time of the bid opening. Failure of the bidder to deliver the quotations on time will result in bid disqualifications: Department of Administration, Purchasing Division, 2019 Washington Street East, P.O. Box 50130, Charleston, WV 25305-0130



Request for Quotation

RFQ NUMBER
BHS10009

PAGE

ADDRESS CORRESPONDENCE TO ATTENTION OF:

ROBERTA WAGNER 804-558-0067

*713133556 800-282-7300 LABORATORY CORPORATION OF AMER 6370 WILCOX ROAD DUBLIN OH 43016-1296

HEALTH AND HUMAN RESOURCES
BBH/HF
ROOM 350

350 CAPITOL STREET CHARLESTON, WV

25301-3702 304-558-3672

| DATE PRINTED | TE | RMS OF SALE | | SHIP VIA | F.O.B. | FREIGHT TERMS |
|--|--|--|-----------------------------------|--|--|-------------------|
| 07/22/2009 | , | | | | | |
| BID OPENING DATÉ: | 08/26/ | 2009 | | BID | OPENING TIME 01 | :30PM |
| LINE | QUANTITY | HOP | CAT. NO | ITEM NUMBER | UNIT PRICE | AMOUNT |
| | | | 140 | | | |
| NOT TIMI REAS | EXCEED T | WELVE NDOR MAGIVING | (12) AY T | E "REASONABLE TI MONTHS DURING ERMINATE THIS CO DIRECTOR OF PUR | THIS "REASONABLE NTRACT FOR ANY | |
| IN T | HIS CONT | RACT DO | CUM | IONS ARE STIPULA ENT, THE TERMS, (FIRM FOR THE LI | CONDITIONS AND | |
| WRITE SUBN DAYS BE I | TEN CONS HITTED TO PRIOR T N ACCORD | ENT OF THE DI O THE E ANCE WI TRACT I | THE IREC EXPI ITH | MAY BE RENEWED OF SPENDING UNIT AND COLUMN DATE. SUGGESTALL BE LIMITED | ND VENDOR, G THIRTY (30) CH RENEWAL SHALL NDITIONS OF THE | |
| RIGI NOTI SUPI | IT TO CAN CE TO TH LIED ARE | CEL THIE VENDO | IS CO OR II INF | | ELY UPON WRITTEN B AND/OR SERVICES DO NOT CONFORM | |
| AUTH MARH ESTI IMME CAUS PORT | ORIZE A ET, WITH MATE, IT DIATE DE | SPENDIN OUT THE EMS SPE LIVERY UDING E | NG U E FI ECIF IN BUT | E DIRECTOR OF PUINT TO PURCHASE (LING OF A REQUISTION THIS CONTROMERGENCIES DUE TO DISTIPLE TO DISTIPLE TO DISTIPLE INCREASE | ON THE OPEN TION OR COST RACT FOR TO UNFORESEEN ELAYS IN TRANS- | |
| , P | | ns only | ζ, в | LISTED IN THE RI ASED ON ESTIMATES PERSE SIDE FOR TERMS AND CON | SUPPLIED BY | |
| SIGNATURE - Ellowell | 2 | | | TELEPHONE 61 | 4-889-1061 DATE | 8/20/09 |
| Vice President | Controller | 13-3° | 75737 | | | TO BE NOTED ABOVE |



VENDOR

State of West Virginia Department of Administration Purchasing Division 2019 Washington Street East Post Office Box 50130 Charleston, WV 25305-0130

Request for Quotation

RFQ NUMBER BHS10009 PAGE 3

ADDRESS CORRESPONDENCE TO ATTENTION OF:

ROBERTA WAGNER B04-558-0067

*713133556 800-282-7300 LABORATORY CORPORATION OF AMER 6370 WILCOX ROAD

DUBLIN OH 43016-1296

HEALTH AND HUMAN RESOURCES BBH/HF

ROOM 350

350 CAPITOL STREET

CHARLESTON, WV

25301-3702

304-558-3672

| DATE PRIN | TED TE | RMS OF SALE | SHIP V | IA . | F.O.B. | FREIGHTTERMS |
|------------------|--|---|--|---|--|-----------------------|
| 07/22/ | | | | | | |
| BID OPENING DATE | 08/26/ | | | BID (| OPENING TIME | 01:30PM |
| LINE | QUANTITY | UOP CAT | ITEM NUM | 1BER | UNIT PRICE | AMOUNT |
| | | | | | FOOD AND AGREED | |
| i . | 1 | DELIVERY D | URING THE | TERM O | THE CONTRACT, | |
| | WRITTEN STAT THE VENDOR F THE ORIGINAL | E CONTRACT OR COMMODI COPY OF T | ORDER (FO FIES COVER HE WV-39 (| ORM NUM RED BY ' SHALL BI | HALL ISSUE A BER WV-39) TO THIS CONTRACT E MAILED TO THE A SECOND COPY | |
| | MAILED TO TH RETAINED BY | E PURCHASI THE SPENDI | NG DIVISIONG UNIT. | ON, AND | A THIRD COPY | |
| | FOR BANKRUPT | CY PROTECT L AND VOID | ION, THE S | STATE M | ONTRACTOR FILES AY DEEM THE SUCH CONTRACT | |
| | SHALL SUPERS CONDITIONS W DOCUMENTS SU | EDE ANY AN HICH MAY A CH AS PRIC R MAINTENAI | D ALL SUBS PPEAR ON A E LISTS, O NCE AGREEN | SEQUENT ANY ATTA ORDER FO MENTS, | ACHED PRINTED | |
| - | REV. 05/26/2 | 009 NOT | ICE | | | |
| j | A SIGNED BID | MUST BE S | JBMITTED I | ro: | | |
| | PURCHAS BUILDIN | ENT OF ADM ING DIVISIO G 15 SHINGTON ST | ON | | | |
| . | CHARLES | | 5305-0130 | | | |
| 0 | | | ERSE SIDE FOR TE | airjana di isidiktri di isidiki di isidik | | |
| SIGNATURE | 10 | | Ī | TELEPHONE 6 | 14-889-1061 | 8/20/04 |
| | ent Controller | 13-375737 | 70 | | | GES TO BE NOTED ABOVE |
| WH | EN RESPONDING | TO REQ INSER | T NAME AND A | ADDRESS I | N SPACE ABOVE LABE | I FD 'VENDOR' |



VENDOR

State of West Virginia Department of Administration Purchasing Division 2019 Washington Street East Post Office Box 50130 Charleston, WV 25305-0130

Request for Quotation

BHS10009

PAGE 4

ADDRESS CORRESPONDENCE TO ATTENTION OF:

304-558-3672

ROBERTA WAGNER 804-558-0067

25301-3702

*713133556 800-282-7300 LABORATORY CORPORATION OF AMER 6370 WILCOX ROAD

DUBLIN OH 43016-1296

HEALTH AND HUMAN RESOURCES
BBH/HF
ROOM 350
T 350 CAPITOL STREET
CHARLESTON, WV

| 07/22/ | <u> </u> |) | MS OF SAL | | SHIPA | (M) | F.O.B. | | FREIGHT TERMS |
|-------------------|--|----------|-----------|------------|------------------|---------|--|-------------|-------------------|
| BID OPENING DATE: | | 08/26/ | 2009 | | 1 | BTD | OPENING TIME | | :30PM |
| LINE | | NTITY | UOP | CAT NO. | ITEM NUI | | UNITPRICE | | AMOUNT |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | N ON THE FACE | OF | |
| | THE EN | AETOBE | OR T | HE Bl. | TON YAM | BE CON | SIDERED: | | |
| | SEALED | BID | | | | | | | |
| | | | | | | | | | |
| | BUYER: | ייים | , | | | | | | |
| | DUIER: | RW-ZI | 4 | | | | ų. | | |
| | RFQ N | о: в | 1S100 |)9 | | | | | |
| | | | | | , | | | | |
| | BID OP | ENING I | DATE: | 08/ | 26/09 | | | | |
| | BID OPI | ENING | CIME: | 1:3 | OPM | | | | |
| | | | | | | | | | |
| | | | ļ | | | | | | |
| | PLEASE | PROVI | DE A F | יא אמי | MBER IN | CASE TT | IS NECESSARY | | |
| | | | | | NG YOUR B | | | | |
| | | | | | 614-761-07 | 91 | | | |
| | - | | | | | | | | |
| | CONTACT | r pers | N (PI | EASE. | PRINT CLI | EARLY): | | | |
| | | | | | Mary Mowry | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | Ī | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| SIGNATURE | <u>, </u> | | | SEE RE | ERSE SIDE FOR TO | | entropological control of the contro | DATE | |
| TITLE TILE | val d | Jun. | | | | 6 | 14-889-1061 | | 8/20/09 |
| Vice Presi | dent Cor | itroller | " 13∡ | 375737 | 'n | | ADDRESS CH | ANGES | TÓ BE NÔTEĎ ABOVE |



VEZDOR

State of West Virginia
Department of Administration
Purchasing Division
2019 Washington Street East Post Office Box 50130 Charleston, WV 25305-0130

Request for

RFO NUMBER BHS10009

| · DΔ | CE | |
|------|----|-------|
| | | - |
| | | |
| | _ | |
| | | |
| | | |

ADDRESS CORRESPONDENCE TO ATTENTION OF:

ROBERTA WAGNER B04-558-0067

*713133556 800-282-7300 LABORATORY CORPORATION OF AMER 6370 WILCOX ROAD

DUBLIN OH 43016-1296

HEALTH AND HUMAN RESOURCES BBH/HF ROOM 350 350 CAPITOL STREET CHARLESTON, WV

25301-3702 304-558-3672

| DATE PRIN | a narah magasan narah ma | len | MS OF SA | LE | | SHIP | /IA | | F.O.B. | | FREIGHT TERMS |
|-----------------------------|--------------------------|---|----------|-----------|--|----------------------|--------------|----------|--------------|--------|-------------------|
| 07/22/ BID OPENING DATE: | 2009 | | | | | | | L | | | |
| BID OPENING DATE: | | 18/26/ | 2009 | • | ta anna di anda ana | and continuous beaut | BID (| OPE | NING TIME | 01 | ;30PM |
| LINE | QUAN | TITY | UOP | CAT NO | | ITEM NU | VIBER | | UNIT PRICE | | AMOUNT |
| | | 200200000000000000000000000000000000000 | | | | | | | | | |
| | | | | | | | | | | | |
| | ***** | THIS | IS T | HE EN | P OF | RFQ | BHS10 | 009 | ***** T | OTAL: | \$526,739.90 |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | • | | | | | | | |
| | | | | | | | | | | | |
| | | | | | 1 | | | | | | |
| | | ļ | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | ! | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | Ì | | | | | | | | | |
| | | | | | | | | | | | • |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | - | | | | | | |
| | | | | | | | | | | | |
| | | 1 | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | SFFRE | /FRSE SI | DE FORT | ERMS AND CON | מודוח | NS. | | |
| IGNATURE | 1 / | <u> </u> | <u> </u> | ومد | 101: 01 | | TELEPHONE 61 | | | DATE | 0/// |
| C 24 | m | حب | | | | | 01 | O | | | 8/20/09 |
| TLE Vice Presi | dent Con | FE troller | | 3-37573 | 370 | | | | ADDRESS C | HANGES | TO BE NOTED ABOVE |
| | EN DECD | | | | T NIANA | | 1000000 | <u> </u> | DAOE ADOVE I | | |

Open End Contract for Reference Laboratory Services BHS10009

1.1 Purpose:

To provide reference laboratory services to the West Virginia Department of Health and Human Resources (WVDHHR), State owned facilities which include: William R. Sharpe, Jr. Hospital, Mildred Mitchell Bateman Hospital, Pinecrest Hospital, Lakin Hospital, Welch Community Hospital, Hopemont Hospital, and John Manchin Sr. Health Care Center, hereafter referred to as "hospitals".

Location of Hospitals:

Pinecrest Hospital 105 S. Eisenhower Drive Beckley, WV 25801 Hopemont Hospital Rt. 3, Box 330 Terra Alta. WV 26764

Lakin Hospital 1 Bateman Circle Lakin, WV 25287 John Manchin Sr. Health Care Center 401 Guffey Street Fairmont, WV 26554

Welch Community Hospital 454 McDowell Street Welch, WV 24801 Mildred Mitchell-Bateman Hospital 1530 Norway Ave. Huntington, WV 25709

William R. Sharpe, Jr. Hospital 936 Sharpe Hospital Road Weston, WV 26452

1.2 Mandatory Requirements

- 1.2.1 The vendor shall provide reference laboratory services to the above listed hospitals.
- The vendor must build, at no expense to the state, the reference laboratory side of a point-to-point interface between the Medsphere Open VistA software and the reference laboratory to facilitate transmission of the electronic laboratory orders from hospitals listed above to the laboratory service. The results of the reference lab specimen analysis will be electronically transmitted back to the Open VistA software for provider review. As a backup, the reference lab shall also print the results at a designated printer at each facility.
- 1.2.3 Standard HL-7 (Help Language 7) version 2.3 formatting rules shall be followed for batch and on-line import/export message segments. VistA provides functionality to print a manifest to accompany the specimen. This manifest provides a check and balance with the electronic order to ensure the order and the physical specimen are correctly matched to the patient.
- Based upon hospital requirements embedded in the electronic lab orders, vendor must telephone positive results and panic or toxic values to hospital(s). Calling arrangements shall be established with each hospital.
- The Vendor must be certified by Clinical Laboratory Improvement Amendments (CLIA) and also must meet all CAP (Certificate of Accreditation) Standards. The Vendor shall provide a copy of Clinical Laboratory Improvement Amendments

- (CLIA) certificate and CAP certificate (Certificate of Accreditation) from the Centers for Medicare & Medicaid Services upon award of contract.
- 1.2.6 Vendor shall operate in accordance with the standards and recommendations of Joint Commission (JC) or other equivalent standards.
- 1.2.7 Vendor must provide courier services seven (7) days per week for collection of specimens. Dependent upon hours of operation and specimen pickup requirements, pickup services would be provided at mutually agreeable times best suited to hospital(s) needs for optimal test result turnaround times.
- Vendor must provide phlebotomy services. Types of services available are to be entered into Exhibit C for information purposes. The need for services varies greatly by hospital and therefore each hospital will be responsible for requesting and scheduling services.
- Vendor must provide routine specimen collection and transport materials and all necessary supplies to hospital(s) for preparation of all specimens for testing. This includes but is not limited to vaccutainer tubes, needles, request forms, preservatives, 24 hour urine containers, cytology and histology containers with preservatives, slides, fixatives, plastic transport bags, centrifuges and directory for all the services offered.
- 1.2.10 Vendor must provide microbiology culture results for the time period based on the standards for the specimen (i.e. blood cultures for seven days). Routine cultures shall have preliminary reports within 24 hours for positive results, then after 48 hours, and final reports within 72 hours of receipt of specimens at the reference laboratory site.
- 1.2.11 Vendor must provide general routine chemistries results within 24 hours of receipt of specimens at the reference laboratory site.
- 1.2.12 Vendor shall provide histology and cytology testing and bacteriology services (cultures and sensitivity) as needed.
- 1.2.13 Vendor must have a CAP and CLIA certified Pathologist who must be available for questions and/or interpretation of positive test results
- 1.2.14 Vendor must assume all responsibility and liability for reading and processing of all cytology and histology specimens.
- 1.2.15 Vendor must retain negative and unsatisfactory PAP slides for five (5) years and positive slides for ten (10) years. Histology slides must be retained for ten (10) years.
- 1 2.16 Vendor must examine, interpret and report results on all slides submitted. Vendor must have written criteria for rejection and for categorizing specimens as unsatisfactory.

1.2.17 Vendor must provide turnaround time for Histology and Cytology PAP results within three (3) days of receipt of slides/specimens, unless further study or staining is required.

Exceptions:

Cytology Turnaround Time

Normal PAP Smear results reporting time – five to seven days. Suspicious, abnormal, unusual specimens or those submitted with insufficient information usually take longer. Any abnormal results must be called to hospital (s).

Surgical Pathology Turnaround Time

Properly submitted specimens are usually processed the next working day. Turnaround time for results is dependent on the complexity of diagnosis and case load. When requested (on the Request Form), a preliminary diagnosis must be available via telephone or computer printer and a final signed report will follow. All numerical abnormal results are to be clearly identified on the report form.

- 1.2.18 The Vendor shall provide the hospital(s) with documentation of quality control measures being performed in the Laboratory upon request. Quality control data, quality assurance policies and results of proficiency testing surveys must be made available upon request.
- 1.2.19 Vendor must have stored lab results available for Quality Assurance monitoring and assessment of laboratory services for at least three (3) years for regular test results and ten (10) years for pathology specimens.
- 1.2.20 Vendor must provide Hospital (s) with statistical reports including the total number of tests performed on a monthly and annual basis by individual testing category.
- 1.2.21 Vendor must provide Hospital(s), on an on-going basis, with the name, address and telephone number of their account representative
- 1.2.22 A list of the type and estimated quantity of tests required by the hospital(s) is attached as Exhibit A. A list of the type and estimated quantity of panels, profiles, screens and cultures is attached as Exhibit B. The lists only represent the most frequently required and/or requested tests needed for evaluation purposes only. Additional types of tests shall be provided by the successful vendor, as ordered by the facilities.
- 2. Method of Evaluation:

The contract will be awarded to the vendor with the lowest total cost for Exhibits A & B and has the ability to provide the Phlebotomy Services (Exhibit C) to the various state facilities.

WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES BHS10009

BUREAU FOR BEHAVIORAL HEALTH AND HEALTH FACILITIES OFFICE OF HEALTH FACILITIES ---- Reference Laboratory Services

Exhibit A

| | BHS10009 | Column A | | Column B | Column C |
|----------------|---------------------------------|--|---------------------|------------------|------------------|
| | EXHIBIT A – Bid Sheet | | | | |
| | | Estimated Annual Volume of Tests | Turn Around Time | Cost Per Test | Total (A x B) |
| | Item Description (Test) | | | | |
| 1 | Acetaminophen | | | | |
| 2 | AFB cu | 94 | | | |
| 3 | AFP Tetra | 120 | | | |
| 4 | Amitriptyline (Elavil) serum | 12 | | | |
| 5 | Ammonia, Plasma | 164 | | | |
| 6 | Amylase, serum | 63 | | | |
| 7 | Anaerobic and aerobic culture | 278 | | | |
| 8 | Antinuclear antibodies (ANA) | 238 | | | |
| 9 | Beta-Hemolytic Strep A | 114 | | | |
| 10 | Bilirubin Total | 42 | | | |
| 11 | Bilirubin, Total/Direct, serum | 24 | | | |
| 12 | BUN | 472 | | | |
| 13 | C. diff. Toxin A | 142 | | | |
| 14 | C-Reactive Protein | 33 | | | |
| 15 | Calcium, serum | 104 | | | |
| 16 | Carbamazepine (Tegretol) | 206 | | | |
| 17 | Chlamydia/GC, DNA Probe | 570 | | | |
| 18 | CBC w/diff - platelet | 5,339 | | | |
| 19 | Chlorpromazine, (Thorazine) | 14 | | <u></u> | |
| 20 | Clomipramine (Anafranil) s. | 14 | | | |
| 21 | Clozapine (clozaril) serum | 76 | | | |
| 22 | Cortisol serum/plasma | 19 | | | |
| 23 | Creatinine Kinase (CK) MB/Total | 63 | | | |
| 24 | Creatinie Kinase, serum | 97 | | | |
| 25 | Creatinine, Serum | 475 | | | |
| 26 | Desipramine, serum | 8 | | | |
| 27 | Digoxin (Lanoxin) | 60 | | | |
| 28 | Estrogen | 4 | | | ļ <u>.</u> |
| 29 | Ethanol serum/blood | 10 | | | |
| 30 | Ethosuximide (Zarontin) serum | 12 | | | <u> </u> |
| 31 | Environmental Culture | 96 | | | |
| 32 | Ferritin | 57 | | | |
| 33 | Fluoxetine (Prozac) serum | 8 | | | |
| 34 | Folates (Folic acid) | 45 | | | |
| 35 | Gabapentin (Neurotin) serum | 22 | | | |
| 36 | Gabritril serum | - | | | |
| 37 | Glucose, 2hr P.P. | 28 | | | |
| 38 | Glucose serum | 127 | | | |

WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES BUREAU FOR BEHAVIORAL HEALTH AND HEALTH FACILITIES OFFICE OF HEALTH FACILITIES ---- Reference Laboratory Services

| ENGLISH COMMUNICATION AND ADDRESS OF THE PARTY OF THE PAR | BHS10009 | Column A | And control to the large of the control and and the control to the control and an analysis of | Column B | Column C |
|--|-------------------------------|--|--|------------------|------------------|
| | EXHIBIT A – Bid Sheet | | | | |
| | | Estimated Annual Volume of Tests | Turn Around Time | Cost Per Test | Total (A x B) |
| 39 | Glucose plasma | 63 | | | |
| 40 | Gynecologic Mono-Layer PAP | 18 | | | |
| 41 | Haloperidol serum | 16 | | | |
| 42 | Hemoglobin A1C | 1,144 | | | |
| 43 | HCG Beta Subunit, Qual (s) | 301 | | | |
| 44 | Helicobacter Pylori, Igg | 14 | | | |
| 45 | Helper T-Lymph – CD4 | 23 | | | |
| 46 | Hepatitis A AB Igm | 28 | | | |
| 47 | Hepatitis A AB, Total | 118 | | | |
| 48 | Hepatitis B Surface AB | 520 | | | |
| 49 | Hepatitis B Surface Ag | 225 | | | |
| 50 | Hepatitis Panel – A, B, C | 168 | | | |
| 51 | HPV | 168 | | | |
| 52 | Imipramine (tofranil) serum | 24 | | | |
| 53 | Insulin, Fasting | 96 | | ļ <u> </u> | |
| 54 | Iron | 56 | | ļ | |
| 55 | Iron/TIBC | 66 | | | |
| 56 | Lamotrigine (Lomictal) serum | 30 | | | |
| 57 | Lead (adult) blood | 210 | | | |
| 58 | Lead (pediatric) blood | 112 | <u> </u> | | |
| 59 | LH & LSH | 95 | | | - |
| 60 | Lipase serum | 130 | | | - |
| 61 | Lithium | 784 | | | |
| 62 | LP Lipo El | 26 | | | |
| 63 | Magnesium, serum | 328 | | | |
| 64 | Microalbumin, 24 hour urine | 17 | | | |
| 65 | Microalbumin, Random urine | 930 | <u> </u> | | |
| 66 | Nortriptyline (Aventyl) serum | 8 | | | |
| 67 | Occult blood (stool) | 30 | | | |
| 68 | Osmolality serum | 88 | | | |
| 69 | Osmolality, urine | 109 | | | |
| 70 | Ova & Parasite | 109 | | | <u> </u> |
| 71 | Perphenazine (Trilafon) | 131 | | | |
| 72 | Phenobarbital serum | 483 | | | |
| 73 | Phenytoin (Dilantin) | 135 | | | |
| 74 | Phosphorus | 129 | | 1 | |
| 75 | Potassium, Serum | 129 | | | |
| 76 | Pregnancy Serum | 105 | | | |
| 77 | Pregnancy Test (Urine) | 61 | | | |
| 78 | Primidone (Mysoline) | 191 | | | |
| 79 | Prolactin | 273 | | | |
| 80 | Prostate-specific AG. Serum | 210 | <u> </u> | 1 | <u> </u> |

WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES BUREAU FOR BEHAVIORAL HEALTH AND HEALTH FACILITIES OFFICE OF HEALTH FACILITIES ---- Reference Laboratory Services

| | BHS10009 | Column A | | Column B | Column C |
|-----|----------------------------------|--|---------------------|------------------|------------------|
| | EXHIBIT A - Bid Sheet | | | | |
| , | | Estimated Annual Volume of Tests | Turn Around Time | Cost Per Test | Total (A x B) |
| 81 | Protein serum | 88 | | | |
| 82 | Prothrombin time | 2,207 | | | |
| 83 | PT & PTT | 568 | | | <u> </u> |
| 84 | Reticulocyte count | 34 | | | |
| 85 | RNA - PCR - Quant. | 27 | | | |
| 86 | STS | 1,202 | | | |
| 87 | Sedimentation rate | 262 | | | |
| 88 | Sodium serum | 379 | | | |
| 89 | T3 - uptake | 64 | | | |
| 90 | T4 | 86 | | | |
| 91 | T-Cell (T-Lymphocyte CD3 Cells) | 16 | | <u> </u> | |
| 92 | Testosterone serum | 37 | - | | |
| 93 | Theophylline serum | 39 | | | |
| 94 | Topiramate (Topamax) serum | 16 | | | |
| 95 | T-Pallidum Ab (FTA-Ab) | 10 | | | |
| 96 | T-Pallidum Antibodies (TP-PA) | 24 | | | |
| 97 | Triglycerides | 42 | | | |
| 98 | Triodothyronine, Free, Serum | 88 | | | |
| 99 | TSH | 190 | | | |
| 100 | TSH 3 rd Generation | 1,302 | <u> </u> | | |
| 101 | UA – Culture reflex | 2,359 | | | |
| 102 | Culture reflex @ additional cost | 1,188 | | | |
| 103 | Uric Acid | 35 | | | |
| 104 | Urinalysis, complete | 3,952 | | | |
| 105 | Valporic acid serum | 2,599 | | | |
| 106 | Variclia Zoster IGG | 28 | | <u> </u> | |
| 107 | Vitamin B-12 | 262 | | | |
| 108 | Vitamin B-12 and Folates | 556 | 1 5 5 6 7 7 7 | N Did Chast | |
| | | To | otal of Exhibit A | 4 – Bia Srieet | <u> </u> |

WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES BUREAU FOR BEHAVIORAL HEALTH AND HEALTH FACILITIES OFFICE OF HEALTH FACILITIES ---- Reference Laboratory Services

| _ | | | _ |
|---------|-----|-----|------------------|
| $ \sim$ | hı | hit | \mathbf{H} |
| L. A | 111 | זומ | \boldsymbol{L} |

| | | chibit B | | | |
|-----|---|---|------------------------|------------------|------------------|
| | | Column A | <u> </u> | Column B | Column C |
| | BHS10009 | | | | |
| | EXHIBIT B | | | | |
| | Most frequently ordered panels profiles, screens and cultures | Estimated Annual Volume of Tests | Turn Around Time | Cost Per Test | Total (A x B) |
| | | | | | |
| | | | | | |
| | | 4500 | | | |
| _1_ | Diagnostic Multi-Chem (28 tests) | 1502 | | | |
| 2 | Albumin, Alkaline Phos, | | | | |
| 3 | ALT-SGPT, AST-SGOT | | | | |
| 4 | BUN, BUN/Creatine | | | | |
| 5_ | Calcium, Chloride | | | | |
| 6 | Cholesterol, Total, Creatine | | | | |
| 7 | GGT ,Glucose, Iron, Total | | | | |
| 8 | LDH, Phospohorous, Potassium, | | | _ | |
| 9 | Sodium, Bilirubin, Total | | | | |
| 10 | Protein, Total, Triglycerides, | | | | |
| 11 | Uric Acid, HDL Cholesterol, | | | | |
| 12 | VLDL Cholesterol, CAL, LDL Cholesterol, Calc, | | | | |
| 13 | T. Choletersterol.HDL Ratio | | | | |
| 14 | Estimated CHD Risk, Globulin, Total, | | | | |
| 15 | A/G Ratio | | | | |
| 16 | AO I (allo | | | | |
| 17 | Thyroid Profiles includes (4 tests) | 1208 | | | |
| | TSH (High Sensitivity, T3 Uptake | 1200 | | | |
| 18 | | 297 | | | |
| 19 | T4 Thyroxine, Free Thyroxine Index | 231 | | <u> </u> | · |
| | Electrolyte Panel includes (3 tests) | 316 | | | |
| 20 | | - 010 | | | |
| 21 | Sodium | | | | |
| 22 | Potassium | | | | |
| 23 | Chloride | | | | |
| 24 | Drug Abuse Screen (seven) Urine, without confirmation | 1256 | | | |
| 25 | Amphetamine, Cocaine | | | | |
| 26 | Barbiturates, Opiates | | | | |
| 27 | Bensodiazepines, Phencyclidine | | | | |
| 28 | Cannabinoid | | | | |
| 20 | Carinaphiolic | | | | |
| 20 | HFP7 & 3AC | 455 | | | |
| 29 | | 100 | | | |
| 30_ | Protein, Total (s), Alkaline Phosphatase(s) | - | | | |
| 31_ | Albumin, (s), LDG, AST (SGOT), GGT | 1 | | | |
| 32 | Bilirubin, Total, Bilbrubin, Direct | | | 1 | l_, |

WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES BUREAU FOR BEHAVIORAL HEALTH AND HEALTH FACILITIES OFFICE OF HEALTH FACILITIES ---- Reference Laboratory Services

| Control to Page 12000 No. 1 | | Column A | | Column B | Column C |
|-----------------------------|--|---|------------------------|------------------|------------------|
| | BHS10009 | | | | |
| | EXHIBIT B | | | | |
| | Most frequently ordered panels profiles, screens and cultures. | Estimated Annual Volume of Tests | Turn Around Time | Cost Per Test | Total (A x B) |
| 33 | Cholesterol, Total | | | | |
| 34 | Cholesterol, Total | | | | |
| 35 | Lipid Profile Four includes: (3 tests) | 5327 | | | |
| 36 | Cholesterol, Total | | | | <u></u> |
| 37 | Triglycerides | | | | · |
| 38_ | HDL Cholesterol | <u> </u> | | | |
| 39 | Drug Abuse Screen, Blood - without confirmation | 831 | | | |
| 40 | Amphetamine, Cocaine | | | | |
| 41 | Barbiturates, Opiates | | | | |
| 42 | Benzodiazepines, Phencycline | | | | |
| 43 | Cannabinoid | | | | |
| | Cultures: | | | | |
| 44 | Lower Respiratory Culture | 107 | | | |
| 45 | Upper Respiratory Culture | 96 | | | |
| 46 | General Bacterial Culture | 137 | | | |
| 47 | Blood Culture | 842 55 | | | |
| 48_ | Stool Culture | 1306 | | | |
| 49 | Urine Culture | 98 | | | |
| 50_ | Sputum Culture | 529 | | | |
| 51 | Sensitivity Organism | 323 | | | |
| 52 | Heavy Metal Profile (Blood) | 21 | | | |
| 53_ | Arsenic | + 1 | | | |
| 54 | Lead | <u> </u> | | | |
| 55 | Mercury | | | | |
| 56 | Hepatitis Profile (Diagnostic follow-up | 46 | | | |
| 57 | HBc Ag; anti-HBc; | | | | |
| 58 | anti-HBS; interpretation | | | | |
| 59 | Hepatitis Profile B & C | 421 | | | |
| 60 | HBs Ag; HBc Ag; Anti-HBC, total | | | | |
| 61 | Anti-HBc; Igm; anti-HBc; anti-HBs | | | | |
| 62 | anti-HCV; interpretation | | | | |
| 63 | Hepatitis Profile A&B | 107 | | | |

WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES BUREAU FOR BEHAVIORAL HEALTH AND HEALTH FACILITIES OFFICE OF HEALTH FACILITIES ---- Reference Laboratory Services

| and the same of th | | Column A | | Column B | Column C |
|--|--|---|------------------------|------------------|------------------|
| | BHS10009 | | | | |
| | EXHIBIT B | | | | |
| | Most frequently ordered panels profiles, screens and cultures. | Estimated Annual Volume of Tests | Turn Around Time | Cost Per Test | Total (A x B) |
| 64 | Anti-HAV; total; anti HAV, Igm; HBs Ag; | | | | |
| 65 | HBc Ag; anti-HBC, total; anti-HBC, lgm; | | | | |
| 66 | anti-HBc; anti-HBS; interpretation | | | | |
| 67 | Hepatitis A Profile | 57 | <u></u> | | · |
| 67 | Anti-HAV, total; anti-HAV, Igm | | | | |
| 68 69 | interpretation | | | | |
| 09 | Interpretation | _ | | | |
| 70 | Hepatitis B Profile | 52 | | | |
| 71 | HBs Ag; HBc Ag; anti-HBc, total | | | | |
| 72 | anti-HBC, Igm; anti-HBc | | | | |
| 73 | anti-HBs; interpretation | | <u> </u> | | |
| 74 | Hepatitis C Virus Antibody | 416 | | | |
| | Additional Cond Outo | | | | |
| 75 | Additional Send Outs: 4 hr. GTT | 6 | | | |
| 76 | Albumin | 129 | <u></u> | | |
| 77 | Alkaline phos panel | 2 | | | |
| 78 | ALT | 112 | | | |
| 79 | ALT - SGOT | 29 | | | |
| 80 | ALT - SGPT | 23 | | | |
| 81 | Amiodarone | 4 | | | |
| 82 | ANC | 80 | | | |
| 83 | AST | 146 | | | |
| 84 | Basic metabolic panel | 70 | | | |
| 85 | B-Type Natriuretic Peptide | 96 | | | |
| 86 | BMP | 188 | | | |
| 87 | CA125 | 4 | <u> </u> | | |
| 88 | CBC | 70 | | | |
| 89 | Chloride | 86 | | | |
| 90 | Cholesterol, Total | 47 | | | |
| 91 | Comp metabolic panel 13 | 214 | | | |
| 92 | Comp metabolic panel 14 | 24 | | | |
| 93 | CPK | 15 | | | |
| 94 | Creatine | 80 | | | |
| 95 | Cystic Fibrosis Profie | 60 | | | |
| 96 | Depakote | 20 | | | |
| 97 | Dilantin | 598 | <u>.</u> | | |
| 98 | Free T4 | 290 | | | J |

WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES BUREAU FOR BEHAVIORAL HEALTH AND HEALTH FACILITIES OFFICE OF HEALTH FACILITIES ---- Reference Laboratory Services

| | | Column A | | Column B | Column C |
|-----|--|---|---|------------------|------------------|
| | BHS10009 | | | | |
| | EXHIBIT B | | | | |
| | Most frequently ordered panels profiles, screens and cultures. | Estimated Annual Volume of Tests | Turn Around Time | Cost Per Test | Total (A x B) |
| 99 | FSH | 50 | | | |
| 100 | FSH and LH | 48 | = | | |
| 101 | Gentamiacin | 2 | | | |
| 102 | GGT | 3 | | | |
| 103 | H&H | 4 | | | |
| 104 | Hematocrit | 10 | | | |
| 105 | Hemoglobin | 10 | | | |
| 106 | HSV culture | 3 | | | |
| 107 | INR | 24 | | | |
| 108 | Ldh | 4 | *************************************** | | |
| 109 | LFT | 45 | 2.20 | | |
| 110 | Mumps IgG | 3 | | | |
| 111 | PAP (Thin Prep) | 478 | | | ** |
| 112 | Pro BNP | 20 | | | |
| 113 | Progesterone | 25 | | | <u></u> |
| 114 | PTH (intact) | 119 | | | |
| 115 | RA panel | 56 | | | |
| 116 | Renal panel | 165 | | | |
| 117 | Rheumatoid Arthritis Factor | 60 | | | · |
| 118 | Rubeola 1Gg | 4 | | | |
| 119 | Teanetal level | 2 | | | |
| 120 | Tegetrol | 2 | | | |
| 121 | Vitamin B 12 and Folate | 180 | | | |
| 122 | Vit. D, 1-125 Dihydroxy | 98 | | | |
| 123 | Vit. D, -25- hydroxyl | 2 | | | |
| 124 | WBC | 508 | | | |
| | | Tota | al of Exhibit E | 3 – Bid Sheet | |

| Total of Exhibit A – Bid Sheet | |
|------------------------------------|--|
| Total of Exhibit B – Bid Sheet | |
| Grand Total = Exhibit A + B | |

EXHIBIT C (Vendor's Attachment of Phlebotomy Services Offered.)

| | Types & Description of Phlebotomy Services Offered |
|---|--|
| 1 | LabCorp will work with the current phlebotomy arrangement at each facility to maintain |
| 2 | the service level. |
| 3 | |

Rev. 09/08

State of West Virginia

VENDOR PREFERENCE CERTIFICATE

Certification and application* is hereby made for Preference in accordance with **West Virginia Code**, §5A-3-37. (Does not apply to construction contracts). **West Virginia Code**, §5A-3-37, provides an opportunity for qualifying vendors to request (at the time of bid) preference for their residency status. Such preference is an evaluation method only and will be applied only to the cost bid in accordance with the **West Virginia Code**. This certificate for application is to be used to request such preference. The Purchasing Division will make the determination of the Resident Vendor Preference, if applicable.

| 1. | Application is made for 2.5% resident vendor preference for the reason checked: Bidder is an individual resident vendor and has resided continuously in West Virginia for four (4) years immediately preceding the date of this certification; or, Bidder is a partnership, association or corporation resident vendor and has maintained its headquarters or principal place of business continuously in West Virginia for four (4) years immediately preceding the date of this certification; or 80% of the ownership interest of Bidder is held by another individual, partnership, association or corporation resident vendor who has maintained its headquarters or principal place of business continuously in West Virginia for four (4) years immediately preceding the date of this certification; or, Bidder is a nonresident vendor which has an affiliate or subsidiary which employs a minimum of one hundred state residents and which has maintained its headquarters or principal place of business within West Virginia continuously for the four (4) years immediately preceding the date of this certification; or, |
|--------------------|--|
| 2. | Application is made for 2.5% resident vendor preference for the reason checked: Bidder is a resident vendor who certifies that, during the life of the contract, on average at least 75% of the employees working on the project being bid are residents of West Virginia who have resided in the state continuously for the two years immediately preceding submission of this bid; or, |
| 3. | Application is made for 2.5% resident vendor preference for the reason checked: Bidder is a nonresident vendor employing a minimum of one hundred state residents or is a nonresident vendor with an affiliate or subsidiary which maintains its headquarters or principal place of business within West Virginia employing a minimum of one hundred state residents who certifies that, during the life of the contract, on average at least 75% of the employees or Bidder's affiliate's or subsidiary's employees are residents of West Virginia who have resided in the state continuously for the two years immediately preceding submission of this bid; or, |
| 4. | Application is made for 5% resident vendor preference for the reason checked: Bidder meets either the requirement of both subdivisions (1) and (2) or subdivision (1) and (3) as stated above; or, |
| 5. | Application is made for 3.5% resident vendor preference who is a veteran for the reason checked: Bidder is an individual resident vendor who is a veteran of the United States armed forces, the reserves or the National Guard and has resided in West Virginia continuously for the four years immediately preceding the date on which the bid is submitted; or, |
| 6. | Application is made for 3.5% resident vendor preference who is a veteran for the reason checked: Bidder is a resident vendor who is a veteran of the United States armed forces, the reserves or the National Guard, if, for purposes of producing or distributing the commodities or completing the project which is the subject of the vendor's bid and continuously over the entire term of the project, on average at least seventy-five percent of the vendor's employees are residents of West Virginia who have resided in the state continuously for the two immediately preceding years. |
| require agains | understands if the Secretary of Revenue determines that a Bidder receiving preference has failed to continue to meet the ments for such preference, the Secretary may order the Director of Purchasing to: (a) reject the bid; or (b) assess a penalty t such Bidder in an amount not to exceed 5% of the bid amount and that such penalty will be paid to the contracting agency acted from any unpaid balance on the contract or purchase order. |
| authori the req | mission of this certificate, Bidder agrees to disclose any reasonably requested information to the Purchasing Division and zes the Department of Revenue to disclose to the Director of Purchasing appropriate information verifying that Bidder has paid juired business taxes, provided that such information does not contain the amounts of taxes paid nor any other information and by the Tax Commissioner to be confidential. |
| and ac | penalty of law for false swearing (West Virginia Code, §61-5-3), Bidder hereby certifies that this certificate is true curate in all respects; and that if a contract is issued to Bidder and if anything contained within this certificate es during the term of the contract, Bidder will notify the Purchasing Division in writing immediately. |
| Bidder | Signed: |
| Date: | Title: |

*Check any combination of preference consideration(s) indicated above, which you are entitled to receive.

STATE OF WEST VIRGINIA Purchasing Division

PURCHASING AFFIDAVIT

VENDOR OWING A DEBT TO THE STATE:

West Virginia Code §5A-3-10a provides that: No contract or renewal of any contract may be awarded by the state or any of its political subdivisions to any vendor or prospective vendor when the vendor or prospective vendor or a related party to the vendor or prospective vendor is a debtor and the debt owed is an amount greater than one thousand dollars in the aggregate.

PUBLIC IMPROVEMENT CONTRACTS & DRUG-FREE WORKPLACE ACT:

If this is a solicitation for a public improvement construction contract, the vendor, by its signature below, affirms that it has a written plan for a drug-free workplace policy in compliance with Article 1D, Chapter 21 of the **West Virginia Code**. The vendor **must** make said affirmation with its bid submission. Further, public improvement construction contract may not be awarded to a vendor who does not have a written plan for a drug-free workplace policy in compliance with Article 1D, Chapter 21 of the **West Virginia Code** and who has not submitted that plan to the appropriate contracting authority in timely fashion. For a vendor who is a subcontractor, compliance with Section 5, Article 1D, Chapter 21 of the **West Virginia Code** may take place before their work on the public improvement is begun.

ANTITRUST:

In submitting a bid to any agency for the state of West Virginia, the bidder offers and agrees that if the bid is accepted the bidder will convey, sell, assign or transfer to the state of West Virginia all rights, title and interest in and to all causes of action it may now or hereafter acquire under the antitrust laws of the United States and the state of West Virginia for price fixing and/or unreasonable restraints of trade relating to the particular commodities or services purchased or acquired by the state of West Virginia. Such assignment shall be made and become effective at the time the purchasing agency tenders the initial payment to the bidder.

I certify that this bid is made without prior understanding, agreement, or connection with any corporation, firm, limited liability company, partnership or person or entity submitting a bid for the same materials, supplies, equipment or services and is in all respects fair and without collusion or fraud. I further certify that I am authorized to sign the certification on behalf of the bidder or this bid.

LICENSING:

Vendors must be licensed and in good standing in accordance with any and all state and local laws and requirements by any state or local agency of West Virginia, including, but not limited to, the West Virginia Secretary of State's Office, the West Virginia Tax Department, West Virginia Insurance Commission, or any other state agencies or political subdivision. Furthermore, the vendor must provide all necessary releases to obtain information to enable the Director or spending unit to verify that the vendor is licensed and in good standing with the above entities.

CONFIDENTIALITY:

The vendor agrees that he or she will not disclose to anyone, directly or indirectly, any such personally identifiable information or other confidential information gained from the agency, unless the individual who is the subject of the information consents to the disclosure in writing or the disclosure is made pursuant to the agency's policies, procedures and rules Vendor further agrees to comply with the Confidentiality Policies and Information Security Accountability Requirements, set forth in http://www.state.wv.us/admin/purchase/privacy/noticeConfidentiality.pdf.

Under penalty of law for false swearing (*West Virginia Code* §61-5-3), it is hereby certified that the vendor affirms and acknowledges the information in this affidavit and is in compliance with the requirements as stated

| Vendor's Name: | Laboratory | Corporation of Ame | rica Holdings | | | |
|------------------------|------------|--------------------|---------------|---|-------|---|
| | | Ehml Om | Date: | 8 | /20/0 | 9 |
| Purchasing Affidavit (| | - | | 7 | | |
| , | • | | | | | |



Request for Quotation

RFQ NUMBER
BHS10009

PAGE 1

ADDRESS CORRESPONDENCE TO ATTENTION OF:

ROBERTA WAGNER

*713133556 800-282-7300 LABORATORY CORPORATION OF AMER 6370 WILCOX ROAD

DUBLIN OH 43016-1296

HEALTH AND HUMAN RESOURCES
H BBH/HF
ROOM 350
I 350 CAPITOL STREET

CHARLESTON, WV

25301-3702 304-558-3672

| DATE PRINTED | TERMS OF S | ALE | SHIP VIA | F.O.B. | FREIGHT TERMS |
|--|-------------|--------------------|---------------------------------|--|---------------------|
| BID OPENING DAYE: | | | | | |
| BID OPENING DATE: | 08/26/2009 | | BID G | PENING TIME 01 | :30PM |
| | NTITY UOP | CAT NO. | ITEM NUMBER | UNIT PRICE | AMOUNT |
| <u> </u> | | | | and the second of the second o | |
| | | | | | |
| | | | ļ | | |
| | | | | | |
| | | | UM NO. 1 | | |
| 1. QUE: | STIONS AND | ANSWERS | ARE ATTACHED. | THE DOCUMENT | |
| | | | | THIS DOCUMENT | |
| | | | | BID. FAILURE TO | ' |
| l i | ND RETURN N | IAY RESU | T.L. IN DISCOUTIL | ICATION OF YOUR | |
| BID. | | | | | |
| | 1 | | | | |
| EXHIBI' | T 10 | | | | |
| | 1 10 | | | | |
| | | | REQUISITION N | O.: BHS10009 | |
| | - | | ~ | | |
| ADDEND | um acknowli | EDGEMENT | | | |
| | | | | | |
| | | | EIPT OF THE FOL | | |
| | | | | REVISIONS TO MY | 7 |
| PROPOS? | al, plans ? | Madous (2) | PECIFICATION, E | TC . | |
| | | | | | |
| ADDEND | UM NO. S: | | | | |
| 1 | . X | | | | |
| 10. 1 | | | | | |
| NTO 2 | g | 1 1 | | | |
| 180 2 | | | | | |
| NO. 3 | | | | | |
| | | | | | |
| NO. 4 | | | | | |
| | | | | | |
| NO. 5 | | | | | 1 |
| | | | | | _ |
| | | | | E RECEIPT OF THE | S |
| ADDENDI | UM(S) MAY E | BE CAUSE | FOR REJECTION | OF BIDS. | |
| | | | | | |
| | | _il _ SEE REVER | L RSE SIDE FOR TERMS AND CON | IDITIONS | |
| SIGNATURE | | <i>T</i> | TELEPHONE 61/ | 4-889-1061 DATE | v// |
| TITLE LIVE SA | THE IN | | 1 012 | | 8/20/09 |
| Vice President Co | ontroller l | 33757370 | | ADDRESS CHANGE | S TO BE NOTED ABOVE |



Request for Quotation

RFQ NUMBER: BHS10009 PAGE 2

ADDRESS CORRESPONDENCE TO ATTENTION OF

ROBERTA WAGNER 3<u>04-558-0067</u>

800-282-7300 LABORATORY CORPORATION OF AMER

6370 WILCOX ROAD

*713133556

DUBLIN OH 43016-1296 HEALTH AND HUMAN RESOURCES

BBH/HF

ROOM 350

350 CAPITOL STREET

CHARLESTON, WV

25301-3702

304-558-3672

| | | · · · · · · · · · · · · · · · · · · · | | | - | | | |
|-------------------|----------------------------|--|--|--------------------|--------------|--|--|-------------------|
| DATE PRIN | TED | TER | MS OF SAL | E | SHIP VIA | | F.O:B. | FREIGHT TERMS |
| BID OPENING DATE: | 2009 | | | | | | | |
| | |)8/26/2 | 009 | 0.020203 | BI | D QPI | ENING TIME 01 | .30PM |
| LINE | QUAI | NTITY | UOP | CAT NO | ITEM NUMBER | | UNIT PRICE | AMOUNT |
| | EPRESE RAL DI ND ANY | ENTATION I | ON MAI ON HE PERS SSUEI S BY | OF A | IS NOT BINDI | MADI S REI NG DED T UM IS SIGNA COMP COMP | E DURING ANY PRESENTATIVES ONLY THE TO THE S BINDING ATURE Oration Of America PANY Egust 20, 2009 | Holdings |
| SIGNATURE | 11/ | 7 | | | TELEPHON | E 614. | -889-1061 DATE | 0//- |
| TITLE CON | -w | de la company de | N . | / | <u> </u> | 014 | 1 | 0/20/09 |
| Vice Preside | ent Cont | roller | " 1/8 | - 37573 | 70 | | ADDRESS CHANGES | TO BE NOTED ABOVE |



Request for Quotation

RFQ NUMBER
BHS10009

| PAC | ìΕ | | |
|-----|----|--|--|
| - | 3 | | |

ADDRESS CORRESPONDENCE TO ATTENTION OF

ROBERTA WAGNER 304-558-0067

*713133556 800-282-7300 LABORATORY CORPORATION OF AMER 6370 WILCOX ROAD

DUBLIN OH 43016-1296

HEALTH AND HUMAN RESOURCES

BBH/HF

ROOM 350

CHARLESTON, WV

25301-3702

304-558-3672

| | PRINTED | TERMS OF SALE | | SHIP VIA | F.O.B. | | FREIGHT TERMS |
|-----------------------|---------------------------------------|--------------------------------|--------------|---------------------|--------------|------------------------------|----------------|
| 08/0 BID OPENING I | 4/2009 PATE: | (26/200 | I | DTD | ODENIANA STA | - 01 20 | |
| LINE | QUANTIT | ^{'26/2009} Y uop | CAT | ITEM NUMBER | OPENING TIM | enenga an-onganongena (nagae | AMQUNT |
| | | | NO. | | | | |
| 001 | | YR 1. | 193-8 | 38 | | | |
| | OPEN END | _ | FOR REFER | RENCE LABORA | TORY SERVIC | ES | |
| | | | | | | | |
| | ****** T | | | DEC DUGIO | | | 524 720 00 |
| 1 | , , , , , , , , , , , , , , , , , , , | HIS IS THE | E END OF | KŁÓ RH2TO | 009 ***** | rotal: | 526,739.90 |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | ļ |
| | | | | | | | |
| SIGNATURE | 2 / 2 | | SEE REVERSES | NDE FOR TERMS AND C | ONDITIONS | IDATE | |
| 1.24 | and In | | | | 14-889-1061 | DATE 8 | 20/09 |
| Vice Pr | esident Cont | roller 13 | -3757370 | | ADDRESS | | BE NOTED ABOVE |

RFQ BHS10009 Addendum #1

Billing Question

Will this be account bill for all patients at the long term care facilities or will we be billing Medicare. If we are to bill Medicare, how will we receive all billing information

Response: Initially the long term care facilities will be billed instead of Medicare, but it is hoped that a remedy for this situation can be found so that Medicare can be billed for our Medicare patients in the future

The West Virginia Department of Health and Human Resources State-Owned Facilities

William R. Sharpe, Jr. Hospital
Mildred Mitchell Bateman Hospital
Pinecrest Hospital
Lakin Hospital
Welch Community Hospital
Hopemont Hospital
John Manchin Sr. Health Care Center

Reference Laboratory Services BHS10009

Laboratory Corporation of America Holdings (LabCorp) Response

Purpose:

1.1 To provide reference laboratory services to the West Virginia Department of Health and Human Resources (WVDHHR), State owned facilities which include: William R. Sharpe, Jr. Hospital, Mildred Mitchell Bateman Hospital, Pinecrest Hospital, Lakin Hospital, Welch Community Hospital, Hopemont Hospital, and John Manchin Sr. Health Care Center, hearafter referred to as "hospitals".

Mandatory Requirements:

- 1.2.2 The vendor must build, at no expense to the state, the reference laboratory side of a point-to-point interface between the Medsphere Open Vista software and the reference laboratory to facilitate transmission of the electronic laboratory orders from hospitals listed above to the laboratory service. The results of the reference lab specimen analysis will be electronically transmitted back to the Open Vista software for provider review. As a backup, the reference lab shall also print the results at a designated printer at each facility.
- **1.2.3** Standard HL-7 (Help Language 7) version 2.3 formatting rules shall be followed for batch and on-line import/export messages segments. Vista provides functionality to print a manifest to accompany the specimen. This manifest provides a check and balance with the electronic order to ensure the order and the physical specimen are correctly matched to the patient.

LabCorp Response

LabCorp can comply to 1.2.2 and 1.2.3

1.2.4 Based upon hospital requirements embedded in the electronic lab orders, vendor must telephone positive results and panic or toxic values to hospital(s). Calling arrangements shall be established with each hospital.

LabCorp Response

LabCorp notifies physicians of **panic results** as soon as possible via telephone, unless otherwise instructed by the client

LabCorp clients can customize how they want to be notified of **alert results**, called during normal business hours. Customers have the option of:

- getting all of the LabCorp Alert tests on the list called at the default values,
- indicating which specific tests and values the client is to be called,
- or, defaulting to getting no alert results called With the advent of electronic and auto-fax reporting capabilities, many customers received their completed patient reports prior to the "normal business hours" alert call Many clients wanted to reduce the time spent on unnecessary or redundant telephone calls.

All results that exceed the normal reference range are flagged as abnormal on the patient result report.

A copy of the Alert result call designation form can be found under TAB 4.

1.2.5 The Vendor must be certified by Clinical Laboratory Improvement Amendments (CLIA) and also must meet all CAP (Certificate of Accreditation) Standards. The Vendor shall provide a copy of Clinical Laboratory Improvement Amendments (CLIA) certificate and CAP certificate (Certificate of Accreditation) from the Center for Medicare and Medicaid Services upon award of contract.

LabCorp Response

LabCorp facilities maintain CAP and CLIA accreditations. Copies of the facility licensures and accreditations for the Dublin, Ohio regional laboratory can be found in **TAB 5**.

1.2.6 Vendor shall operate in accordance with the standards and recommendations of Joint Commission (JC) or other equivalent standards.

LabCorp Response

Although the Joint Committee on Accreditation of Healthcare Organizations ("JCAHO") requires similar proficiency testing as CAP, JCAHO no longer offers accreditation to independent reference laboratories. All LabCorp facilities performing under this contract maintain the necessary laboratory licensure/credentials as determined by their level of testing.

1.2.7 Vendor must provide courier services seven (7) days per week for collection of specimens. Dependent upon hours of operation and specimen pickup requirements, pickup services would be provided at mutually agreeable times best suited to hospital(s) needs for optimal test result turnaround times.

LabCorp Response

LabCorp's courier service is critical as the first point of contact in the turn-around time process. Our couriers provide direct specimen receipt, a controlled environment for specimen transport and delivery of necessary supplies. The courier personnel are generally employees of LabCorp, trained in the proper handling and transportation of various specimen types, such as frozen and room temperature samples. Dependent on

hours of operation and specimen pickup requirements, mutually agreeable times could be scheduled to meet these specific needs, including multiple daily pick-ups consistent with LabCorp policies.

1.2.8 Vendor must provide phlebotomy service. Types of services available are to be entered into Exhibit C for information purposes. The need for services varies greatly by hospital by hospital and therefore each hospital will be responsible for requesting and scheduling services.

LabCorp Response

LabCorp will work with the current phlebotomy arrangement at each facility to maintain the service level

1.2.9 Vendor must provide routine specimen collection and transport materials and all necessary supplies to hospital(s) for preparation of all specimens for testing. This includes but is not limited to vacccutainer tubes, needles, request forms, preservatives, 24 hour urine containers, cytology and histology containers with preservatives, slides, fixatives, plastic transport bags, centrifuges and directory for all the services offered.

LabCorp Response

As permitted by applicable law, LabCorp provides its clients with routine specimen collection and transport materials for specimens that are analyzed within our laboratory network. A sample supply requisition in **TAB 6** has been provided for your reference

- **1.2.10** Vendor must provide microbiology culture results for the time period based on the standards for specimen (i.e. blood cultures for seven days). Routine cultures shall have preliminary reports with 24 hours for positive results, then after 48 hours, and final reports within 72 hours of receipt of specimens at the reference laboratory site.
- **1.2.11** Vendor must provide general routine chemistries results with 24 hours of receipt of specimens a the reference laboratory site.

LabCorp Response to 1.2.10 & 1.2.11

Routine tests are typically reported within 24 hours of receipt of the specimen by the testing facility. Significant anomalies may require more time. Esoteric tests that cannot be processed at a regional laboratory will be transported to one of our esoteric laboratories.

1.2.13 Vendor must have a CAP and CLIA certified Pathologist who must be available for questions and/or interpretation of positive test results.

LabCorp Response

LabCorp can comply

1.2.15 Vendor must retain negative and unsatisfactory Pap slides for five (5) years and positive slides for (10) years. Histology slides must be retained for ten (10) years.

LabCorp Response

LabCorp retains pap slides for 5 years, regardless of the diagnosis, as required by CAP and LabCorp company policy. Histology slides are retained for 10 years.

1.2.16 Vendor must examine, interpret and report results on all slides submitted. Vendor must have written criteria for rejection and for categorizing specimens as unsatisfactory.

<u>LabCorp Response</u> Reporting Tests Not Performed (TNP)

LabCorp is responsible for communicating the result(s) of all tests ordered by LabCorp clients. This responsibility extends to those tests where LabCorp is not able to provide a result. There are three common scenarios where LabCorp must report a TNP (test not performed) to clients:

- 1 Pre-analytical problems such as receiving the incorrect specimen for a given test, or no test requested for a specimen.
- 2. Specimen Rejection Where the condition of the specimen is such that testing cannot be performed, such as: Insufficient quantity, Hemolysis or Wrong pH.
- 3. Lab Identified Specimen Quality Issues Where an accident occurred such that testing is no longer possible, such as: Lost sample, Thawed sample, or Broken sample.

LabCorp communicates this information to the client by adding the appropriate explanation to the patient's report. In some instances, this is followed up with a phone call to the client to alert them to the problem.

1.2.17 Vendor must provide turnaround time for Histology and Cytology PAP results within three (3) days of receipt of slides/specimens, unless further study or staining is required.

Exceptions:

Normal PAP Smears results reporting time – five to seven days.

Suspicious, abnormal, unusual specimens or those submitted with insufficient information usually take longer. Any abnormal results must be called to hospital (s).

LabCorp Response

LabCorp normal turn around time for Cytology specimens is 5 Days and turn around time for Histology specimens is 2-4 days. Abnormal results notification can be customized by submitting the Alert Result Call Designation Form A copy of the Alert result call designation form can be found under **TAB 4**.

1.2.18 The Vendor shall provide the hospital(s) with documentation of quality control measures being performed in the Laboratory upon request. Quality control data, quality assurance policies and results of proficiency testing surveys must be made available upon request.

LabCorp Response

At LabCorp, quality is never compromised. Test results from every section of the laboratory are routinely monitored for reliability, precision, and accuracy by both internal and external quality control programs LabCorp voluntarily participates in more than 20 external quality control programs and is inspected regularly by state, federal, and private accrediting agencies.

- Quality Assurance/Quality Control Programs Quality assurance (QA) and quality control (QC) are
 integral parts of LabCorp's daily operation. LabCorp uses both internal and external systems to monitor
 the accuracy and precision of patient runs for assays performed in LabCorp facilities
- Organization LabCorp's QA and QC programs are overseen and administered by dedicated laboratory professionals, working full-time for the improvement of testing quality. A corporate quality group provides direction for the overall program in quality. Standardized QA programs are implemented and monitored by QA managers located in each of the operating divisions throughout the country. Also, each major laboratory has a full time QA coordinator who is responsible for quality activities at that laboratory site and reports to the divisional QA manager.
- Corporate QA Mission Statement To facilitate the delivery of accurate testing and reporting to our customers by providing high quality programs, information, standardized policies, and training materials to our laboratories.
- Quality Assurance (QA) Plans Personnel at each laboratory facility develop written QA plan
 documents that specify a systematic process for monitoring and evaluating testing quality and resolving
 identified concerns. Testing quality is monitored and evaluated through (1) the routine collection of
 information about various aspects of lab operations and testing and (2) periodic assessment of
 collected information in order to identify and address concerns about testing quality and opportunities
 for improvement.
 - A QA committee, consisting of laboratorians and service staff, meets regularly at each lab site to review performance monitors and to resolve issues that lead to a monitor's "threshold" level being exceeded. The committee also evaluates the effectiveness of remedial actions taken. The effectiveness of the overall plan and the appropriateness of each quality monitor are reviewed on an annual basis.
- Internal Quality Control (QC) LabCorp's national quality control (QC) program allows for the
 assessment of accuracy and precision of patient results generated by our laboratories. Control samples
 with known analyte concentrations are routinely interspersed and analyzed with patient samples
 submitted for testing. Our computerized control algorithms, based on the widely accepted, state-of-theart Westgard rules, alert the testing analyst of statistically or clinically significant analytical anomalies as
 they occur during the run. The analyst is charged with taking immediate and appropriate corrective
 action. This highly responsive computer-assisted quality control process helps to detect and correct
 potentially erroneous results before they are released to clients

More than 200,000 individual QC values are reviewed to detect systematic (accuracy) and random (precision) errors each month by the Burlington, North Carolina, reference facility. In addition, more than 1 9 million QC values are generated for evaluation each month by LabCorp's facilities nationwide.

Retrospective on-line QC inquiry for any LabCorp test is available to lab technicians, technologists, and supervisors via the laboratory computer system. This valuable QC information provides up-to-date feedback to the technologist and lab directors on the performance of the assay. Quantitative QC data, including monthly lot-to-date and cumulative statistics, are summarized in graphic format each month for retrospective review by department personnel.

In order to compare testing quality throughout the LabCorp network of laboratories, LabCorp's individual laboratory computer systems are linked together. A national QC database, containing all quantitative QC results, has been compiled. A computer program checks this database for any bias between laboratories and identifies any significant exceptions. This system ensures that consistently high quality results are generated by every LabCorp facility.

- Internal Proficiencies Testing LabCorp has an extensive, internally administered program of blind sample proficiency testing in which laboratories receive test samples from the quality assurance and corporate technical services departments for analysis. Results are graded and summarized by LabCorp's corporate QA group and distributed to the laboratory directors for evaluation and follow-up. This internal proficiency program serves to test LabCorp's complete testing service: specimen logistics, order entry and accessioning systems, accuracy and precision of its testing protocols, technologist/technician performance, quality assurance reporting checks, and turnaround time from specimen pick-up to final reporting. This monthly program serves to supplement the external proficiency programs supplied by the laboratory accrediting agencies.
- External Proficiency Testing LabCorp participates in numerous externally administered blind quality surveillance programs, including the College of American Pathologists (CAP) program Consistently acceptable performance on these surveys is a prerequisite for continued licensure and certification. LabCorp voluntarily participates in more than 15 external quality control programs.

Significant findings from the internal and the external proficiency programs are reviewed at the national level and summarized in a monthly report called a "watch list." Monthly summaries are submitted to senior LabCorp management. The internal and external proficiency programs supplement other QA procedures and provide LabCorp's management with monitors that can be used to review technical and service performance from the user's perspective.

These programs facilitate the evaluation of LabCorp's primary program for internal quality assurance, which emphasizes the use of controls during the testing process

- Internal Inspections The LabCorp divisional QA managers perform regular internal inspections at the laboratories within their division and audit compliance with federal and state regulations. Deficiencies are corrected with the help of laboratory managers and directors. This ensures that all laboratories within LabCorp perform at a high level of quality.
- Quality Assessment Reporting The LabCorp quality assessment program is an ongoing process of
 comparing actual performance to the desired performance goals detailed in the quality plan. To our
 clients, laboratory quality is more than just accurate test results. It consists of all facets of our laboratory
 service, including turnaround time, client services, patient satisfaction, billing, etc. Our quality plan is the
 yardstick against which all of our daily activities are measured. Using quality assessment techniques,
 LabCorp locations have created a variety of programs to monitor critical aspects of providing results and

services to our customers. Knowing customers' needs, wants, and expectations and then evaluating our ability to meet them are a part of the LabCorp quality commitment

External measures of quality are taken continuously at all LabCorp locations and rolled-up monthly into national reports. These reports provide an overview of our performance on various aspects of patient care called for in our QA plans. These reports include:

- Client Concerns This report provides an early indicator of laboratory concerns and details the number of client inquiries received by our laboratories. These reports include categories from all facets of LabCorp operations, including pre-analytic (phone response, courier pick-up), analytic (turnaround time, specimen handling, etc), and post-analytic (reporting, billing) client concerns.
- Laboratory Corrected Reports Client reports that were modified, corrected, and then reissued are
 tracked. These errors are also categorized as pre-analytic (specimen identification errors, incorrect test
 numbers), analytic (technical errors), and post-analytic (result entry, transcription errors) types of errors
- Managed Care QA Monitors Reporting Large managed care groups now require that LabCorp provide them with summary reports on various aspects of patient care that they consider "quality monitors" of LabCorp's performance These quality monitors include (1) licensure/accreditation, (2) client service response, (3) proficiency testing, and (4) turnaround time The divisional QA managers produce the managed care reports that are required by groups in their division Quality metrics are also converted to a six-sigma scale, so that they may be benchmarked against industry standards
- Standardization The QA department works with LabCorp's science and technology group to assure
 that standard analytical methods are used by LabCorp's various labs. Our standardization philosophy is
 unique in the industry in that it provides a uniform level of result quality throughout all laboratory
 facilities. This further ensures that quality is consistent from location.

Results from many of our locations that employ identical methodologies can be used interchangeably Health care organizations and providers recognize the advantage of not having to adjust their practice parameters to geographic laboratory result and reference interval variations.

- Corporate Quality Policies The corporate QA group, working with committees consisting of
 divisional QA managers and laboratorians, formulates and issues corporate policies that provide
 direction on key quality areas of concern in the laboratory. These policies, which allow LabCorp to
 standardize its approach to quality in various areas, address such issues as specimen identification,
 alert/panic value reporting, and corrected reports In addition, a lab certification manual that details
 accepted laboratory protocols has been prepared to assist labs in maintaining acceptable levels of
 quality and in meeting all federal and state regulatory requirements.
- **1.2.19** Vendor must have stored lab results available for Quality Assurance monitoring and assessment of laboratory services for at least three (3) years for regular test results and ten (10) years for pathology specimens.

<u>LabCorp Response</u> LabCorp can comply. **1.2.20** Vendor must provide Hospital(s) with statistical reports including the total number of test performed on a monthly and annual basis by individual testing category.

LabCorp Response

LabCorp maintains an array of utilization options, which may benefit the facilities. LabCorp maintains flexibility with respect to reporting options and can provide certain customized reports. Available fields for report customization includes, test number, test name, client price, current price, current month and year to date test quantity, and current month and year-to-date net revenues.

LabCorp recognizes that various levels of summary reporting may be required for aggregated reviews of test usage. To that end, grouping and summarizing of individual accounts totals are also available through the utilization packages offered at LabCorp. In addition to the individual accounts totals, groups of accounts may be established for facility, and/or association totals. These reporting options may be provided in hard-copy or electronic format. Copies of sample reports can be found under TAB 7.

Standard Utilization Report (Order #RCMB015 - A)

This report provides clients with account data for book keeping purposes. LabCorp Test Code Number and Test Name, Test Price, Current Month Quantity (how many of the test were ordered that month), Current Month Dollars (test quantity times test price), and Year-To-Date Quantity, and Year-To-Date Dollars.

Standard Utilization Report Without Pricing (Order #RCMB015 - B)

The same report as above without the pricing information: LabCorp Test Code Number and Test Name, Current Month Quantity, and Year-To-Date Quantity.

Physician Level Utilization Report with Formularies (RCMB015 - D)

This report was created to help our clients monitor their individual physicians' ordering patterns. It provides clients with account data sorted by account number, ordering physician, and then by ordered tests. Each test is categorized as either a "Formulary Test" or a "Non-Formulary Test". The "Formulary" is a group of tests put together and recommended for use by the client's Corporate Medical Director. Formulary and Non-Formulary Sub Totals will only be provided if an account supplies LabCorp with the list of tests they want to monitor. The report also exhibits account pricing.

Physician Level Utilization Report without Formularies (RCMB015-E)

This report is identical to the previous report without categorizing tests as "Formulary" or "Non-Formulary."

Year-To-Date Utilization Report (RCMB015-G)

This report supplies the volume of tests ordered and the **adjusted** (e.g., includes any credits issued) dollars cumulatively from January to the last month that has been through an end of the month production cycle. The report is sorted by quantity in descending order and shows the account quantity and dollar totals at the bottom of the report.

Standard Utilization Report by Line of Business (RCMB015-H)

This summary report shows tests ordered sorted by account number and then sorted again by the line of business within the account. The line of business codes are CM = Commercial, MC = Medicare, PI = Private Insurance, PT = Patient, MD = Medicaid. This report is sorted in alphabetical order by test name

West Virginia Department of Health and Human Resources Bureau for Behavioral Health and Health Facilities Office of Health Facilities ---- Reference Laboratory Services

BHS10009

EXHIBIT A

| | BHS10009 | | | COLUMN A | | COLUMN B | COLUMN C |
|----|---------------------------------|--------|--------------------------------|---|---------------------|------------------|------------------|
| | EXHIBIT - A- Bid Sheet | | | | | | |
| | Item Description (Test) | Test# | LabCorp Description | Estimated Annual Volume of Tests | Turn Around Time | Cost Per Test | Total (A x B) |
| 1 | Acetaminophen | | Acetaminophen (Tylenol), Serum | - | 2 Days | \$98.25 | \$0.00 |
| | AFB cu | | AFB Culture and Smear, Broth | 94 | 42-56 Days | \$35.00 | \$3,290.00 |
| | AFP Tetra | | AFP Tetra | 120 | 3 days | \$50.00 | \$6,000.00 |
| 4 | Amitriptyline (Elavil) serum | 007476 | Amitriptyline (Elavil), Serum | 12 | 1 Day | \$63.63 | \$763.56 |
| 5 | Ammonia, Plasma | 007054 | Ammonia, Plasma | 164 | 1 Day | \$12.00 | \$1,968.00 |
| | Amylase, serum | 001396 | Amylase, Serum | 63 | 1 Day | \$3.75 | \$236.25 |
| 7 | Anaerobic and aerobic culture | 008003 | Anaerobic and Aerobic Culture | 278 | 4 Days | \$29.00 | \$8,062.00 |
| 8 | Antinuclear antibodies (ANA) | 164855 | ANA Qualitative | 238 | 1 Day | \$6.00 | \$1,428.00 |
| 9 | Beta-Hemolytic Strep A | 008169 | Beta Strep GP A Culture | 114 | 1-2 Days | \$5.50 | \$627.00 |
| 10 | Bilirubin Total | 001099 | Bilirubin, Total | 42 | 1 Day | \$2.75 | \$115.50 |
| 11 | Bilirubin, Total /Direct, serum | 001214 | Bilirubin, Total/Direct, Serum | 24 | 1 Day | \$2.85 | \$68.40 |
| | BUN | 001040 | BUN | 472 | 1 Day | \$2.75 | \$1,298.00 |
| | C. diff. Toxin A | 086207 | C difficile Toxins A+B, EIA | 142 | 1 Day | \$11.00 | \$1,562.00 |
| 14 | C-Reactive Protein | 006627 | C-Reactive Protein, Quant | 33 | 1 Day | \$5.50 | \$181.50 |
| 15 | Calcium, serum | 001016 | Calcium, Serum | 104 | 1 Day | \$2.75 | \$286.00 |
| 16 | Carbamazepine (Tegretol) | 007419 | Carbamazepine(Tegretol), Serum | 206 | 1 Day | \$10.00 | \$2,060.00 |
| 17 | Chlamydia/GC, DNA Probe | 096479 | Chlamydia/Gonococcus DNA Probe | 570 | 2 Days | \$14.00 | \$7,980.00 |
| 18 | CBC w/diff - platelet | 005009 | CBC With Differential/Platelet | 5,339 | 1 Day | \$3.00 | \$16,017.00 |
| 19 | Chlorpromazine, (Thorazine) | 072132 | Chlorpromazine, Serum | 14 | 1 Day | \$66.88 | \$936.32 |
| 20 | Clomipramine (Anafranil) s. | 706465 | CLOMIPRAMINE, SERUM | 14 | 1 Day | \$58.38 | \$817.32 |
| | Clozapine (clozaril) serum | 706440 | CLOZAPINE (CLOZARIL), SERUM | 76 | 1 Day | \$35.00 | \$2,660.00 |
| 22 | Cortisol serum/plasma | 004051 | Cortisol | 19 | 1 Day | \$8.00 | \$152.00 |
| 23 | Creatinine Kinase (CK) MB/Total | 002311 | Creatine Kinase (CK), MB/Total | 63 | 1 Day | \$25.00 | \$1,575.00 |
| 24 | Creatinie Kinase, serum | 001362 | Creatine Kinase, Total, Serum | 97 | 1 Day | \$2.75 | \$266.75 |
| 25 | Creatinine, serum | 001370 | Creatinine, Serum | 475 | 1 Day | \$2.75 | \$1,306.25 |
| 26 | Desipramine, serum | 007765 | Desipramine, Serum | 8 | 1 Day | \$65.00 | \$520.00 |
| 27 | Digoxin (Lanoxin) | 007385 | Digoxin (Lanoxin), Serum | 60 | 1 Day | \$6.00 | \$360.00 |
| 28 | Estrogen | 004549 | Estrogens, Total | 4 | 1 Day | \$61.38 | \$245.52 |
| | Ethanol serum / blood | | Ethanol, Blood | 10 | 1 Day | \$44.25 | \$442.50 |
| 30 | Ethosuximide (Zarontin) serum | 007443 | Ethosuximide (Zarontin), Serum | 12 | 1 Day | \$49.13 | \$589.56 |
| 31 | Environmental Culture | 008557 | Environmental Culture | 96 | 2 Days | \$8.50 | \$816.00 |
| 32 | Ferritin | 004598 | Ferritin, Serum | 57 | 1 Day | \$5.00 | \$285.00 |
| 33 | Fluoxetin (Prozac) serum | 706838 | FLUOXETINE (PROZAC), SERUM | 8 | 1 Day | \$70.50 | \$564.00 |
| 34 | Folates (Folic acid) | 002014 | Folates (Folic Acid), Serum | 45 | 1 Day | \$5.50 | \$247.50 |
| 35 | Gabapentin (neurotin) serum | 716811 | GABAPENTIN (NEURONTIN), SERUM | 22 | 1 Day | \$133.25 | \$2,931.50 |
| 36 | Gabritril serum | 842104 | Tiagabine (Gabitril) | - | SEND-OUT TEST | \$101.75 | \$0.00 |
| 37 | Glucose, 2 hr P.P. | 002022 | Glucose, Two-Hour Postprandial | 28 | 1 Day | \$2.75 | \$77.00 |
| | Glucose serum | 001032 | Glucose, Serum | 127 | 1 Day | \$2.75 | \$349.25 |
| | Glucose plasma | | Glucose, Plasma | 63 | 1 Day | \$2.75 | \$173.25 |
| | Gynecologic Mono-Layer PAP | 1 | Gynecologic Mono-layer Pap | 18 | 5 Days | \$24.00 | \$432.00 |

West Virginia Department of Health and Human Resources Bureau for Behavioral Health and Health Facilities Office of Health Facilities ---- Reference Laboratory Services

BHS10009

EXHIBIT A

| | BHS10009 | | | COLUMN A | | COLUMN B | COLUMN C |
|------|-------------------------------|--------|--------------------------------|---|---------------------|------------------|------------------|
| | EXHIBIT - A- Bid Sheet | | | | | | |
| | Item Description (Test) | Test # | LabCorp Description | Estimated Annual Volume of Tests | Turn Around Time | Cost Per Test | Total (A x B) |
| 41 | Haloperidol serum | | Haloperidol (Haldol), Serum | 16 | 1 Day | \$73.75 | \$1,180.00 |
| 42 | Hemoglobin A1C | | Hemoglobin A1c | 1,144 | 1 Day | \$5.00 | \$5,720.00 |
| 43 | HCG Beta Subunit, Qual (s) | 004556 | hCG, Beta Subunit, Qual, Serum | 301 | 1 Day | \$8.00 | \$2,408.00 |
| 44 | Helicobacter Pylori, Igg | 1 | H. Pylori IgG, ABS | 14 | 1 Day | \$48.63 | \$680.82 |
| 45 | Helper T-Lymph - CD4 | | Helper T-Lymph-CD4 | 23 | 2 Days | \$30.00 | \$690.00 |
| 46 | Hepatitis A AB Igm | | Hep A Ab, IgM | 28 | 1 Day | \$8.50 | \$238.00 |
| 47 | Hepatitis A AB, Total | 1 | Hep A Ab, Total | 118 | 1 Day | \$6.00 | \$708.00 |
| 48 | Hepatitis B Surface AB | 006395 | Hep B Surface Ab | 520 | 1 Day | \$7.00 | \$3,640.00 |
| 49 | Hepatitis B Surface Ag | 006510 | Hep B Surface Ag | 225 | 1 Day | \$5.00 | \$1,125.00 |
| | Hepatitis Panel - A,B,C | 322744 | Hepatitis Panel (4) | 168 | 1 Day | \$28.50 | \$4,788.00 |
| | HPV | 1 | HPV Hybrid Capture High Risk | 168 | 2 Days | \$42.00 | \$7,056.00 |
| 52 | Imipramine (tofranil)serum | I | Imipramine (Tofranil), Serum | 24 | 1 Day | \$18.00 | \$432.00 |
| 53 | Insulin, Fasting | | Insulin, Fasting | 96 | 1 Day | \$6.00 | \$576.00 |
| | Iron | 001339 | Iron, Serum | 56 | 1 Day | \$2.75 | \$154.00 |
| | Iron / TIBC | 001321 | Iron and TIBC | 66 | 1 Day | \$6.00 | \$396.00 |
| - 50 | | | | | | | |
| 56 | Lamotrigine (Lomictal) serum | | LAMOTRIGINE (LAMICTAL), SERUM | 30 | 1 Day | \$35.00 | \$1,050.00 |
| 57 | Lead (adult) blood | 007625 | Lead, Blood (Adult) | 210 | 1 Day | \$8.00 | \$1,680.00 |
| 58 | Lead (pediatric) blood | 717009 | Lead, Blood (Pediatric) | 112 | 1 Day | \$8.00 | \$896.00 |
| 59 | LH & LSH | 028480 | FSH and LH | 95 | 1 Day | \$18.00 | \$1,710.00 |
| 60 | Lipase serum | 001404 | Lipase, Serum | 130 | 1 Day | \$3.75 | \$487.50 |
| 61 | Lithium | 007708 | Lithium (Eskalith), Serum | 784 | 1 Day | \$6.00 | \$4,704.00 |
| 62 | LP Lipo El | 235036 | LP+LipoEl | 26 | 4 Days | \$12.00 | \$312.00 |
| 63 | Magnesium, serum | I | Magnesium, Serum | 328 | 1 Day | \$4.50 | \$1,476.00 |
| 64 | Microalbumin, 24 hour urine | I | Microalbumin, 24 hr Urine | 17 | 1 Day | \$4.25 | \$72.25 |
| 65 | Microalbumin, Random urine | I | Microalbumin, Random Urine | 930 | 1 Day | \$4.25 | \$3,952.50 |
| 66 | Nortriptyline (Aventyl) serum | | Nortriptyline (Aventyl), Serum | 8 | 1 Day | \$64.50 | \$516.00 |
| 67 | Occult blood (stool) | i | Occult Blood, Stool | 30 | 1 Day | \$6.00 | \$180.00 |
| 68 | Osmolality serum | 002071 | Osmolality, Serum | 20 | 1 Day | \$5.00 | |
| 69 | Osmolality, urine | 003442 | Osmolality, Urine | 88 | 1 Day | \$5.00 | \$440.00 |
| 70 | Ova & Parasite | 008623 | Ova + Parasite Exam | 109 | 2 Days | \$10.00 | \$1,090.00 |
| | | 244040 | (T.11-6-1) | 40 | SEND-OUT | **** | ¢000 c0 |
| | Perphenazine (Trilafon) | | Perphenazine (Trilafon) | 10 | TEST | \$98.25 | \$982.50 |
| 72 | Phenobarbital serum | | Phenobarbital, Serum | 131 | 1 Day | \$12.00 | \$1,572.00 |
| 73 | Phenytoin (Dilantin) | 007401 | Phenytoin (Dilantin), Serum | 483 | 1 Day | \$10.00 | \$4,830.00 |
| 74 | Phosphorus | | Phosphorus, Serum | 135 | 1 Day | \$2.75 | \$371.25 |
| 75 | Potassium, Serum | | Potassium, Serum | 129 | 1 Day | \$2.75 | \$354.75 |
| | Pregnancy Serum | 1 | hCG, Beta Subunit, Qnt, Serum | 12 | 1 Day | \$9.00 | \$108.00 |
| 77 | Pregnancy Test (Urine) | | Pregnancy Test, Urine | 105 | 1 Day | \$7.00 | \$735.00 |
| 78 | Primidone (Mysoline) | | Primidone (Mysoline), Serum | 61 | 1 Day | \$20.00 | \$1,220.00 |
| 79 | Prolactin | 004465 | Prolactin | 191 | 1 Day | \$9.00 | |
| 80 | Prostate-specific AG. Serum | 010322 | Prostate-Specific Ag, Serum | 273 | 1 Day | \$7.00 | \$1,911.00 |

West Virginia Department of Health and Human Resources Bureau for Behavioral Health and Health Facilities Office of Health Facilities ---- Reference Laboratory Services BHS10009

EXHIBIT A

| | BHS10009 | | | COLUMN A | | COLUMN B | COLUMN C |
|-----|----------------------------------|--------|---|----------------------------------|---------------------|------------------|------------------|
| | EXHIBIT - A- Bid Sheet | | | | | | · |
| | Item Description (Test) | Test# | LabCorp Description | Estimated Annual Volume of Tests | Turn Around Time | Cost Per Test | Total (A x B) |
| 81 | Protein serum | | Protein, Total, Serum | 88 | 1 Day | \$2.75 | \$242.00 |
| 82 | Prothrombin time | | Prothrombin Time (PT) | 2,207 | 1 Day | \$3.00 | \$6,621.00 |
| | PT & PTT | 020321 | PT AND PTT | 568 | 1 Day | \$6.00 | \$3,408.00 |
| | Reticulocyte count | 005280 | Reticulocyte Count | 34 | 1 Day | \$4.00 | \$136.00 |
| | RNA - PCR - Quant. | 550430 | RNA, Real Time PCR (Non-Graph) | 27 | 5-6 Days | \$90.00 | \$2,430.00 |
| 86 | STS | 006460 | Rapid Plasma Reagin, Quant | 1,202 | 1 Day | \$4.50 | \$5,409.00 |
| 87 | Sedimentation Rate | 005215 | Sedimentation Rate-Westergren | 262 | 1 Day | \$3.50 | \$917.00 |
| 88 | Sodium serum | 001198 | Sodium, Serum | 379 | 1 Day | \$2.75 | \$1,042.25 |
| | T3 - uptake | 001156 | T3 Uptake | 64 | 1 Day | \$3.25 | \$208.00 |
| 90 | T4 | 001149 | Thyroxine (T4) | 86 | 1 Day | \$3.25 | \$279.50 |
| 91 | T-Cell (T-Lymphocyte CD3 Cells) | 096834 | T-Lymphocyte CD3 Cells | 16 | 1 Day | \$130.75 | \$2,092.00 |
| 92 | Testosterone serum | 004226 | Testosterone, Serum | 37 | 1 Day | \$9.00 | \$333.00 |
| 93 | Theophylline serum | 007336 | Theophylline, Serum | 39 | 1 Day | \$10.00 | \$390.00 |
| 94 | Topiramate (Topamax) serum | 716285 | TOPIRAMATE (TOPAMAX), SERUM | 16 | 1 Day | \$135.25 | \$2,164.00 |
| 95 | T-Pallidum Ab (FTA-Ab) | 006379 | T pallidum Ab (FTA-Ab) | 10 | 1/2 IF REPEAT-ED | \$39.88 | \$398.80 |
| 96 | T-Pallidum Antibodies (TP-PA) | 082339 | T pallidum Antibodies (TP-PA) | 24 | 1-2 Days | \$11.00 | \$264.00 |
| 97 | Triglycerides | 001172 | Triglycerides | 42 | 1 Day | \$2.75 | \$115.50 |
| 98 | Triodothyronine, Free, Serum | 010389 | Triiodothyronine, Free, Serum | 88 | 1 Day | \$16.00 | \$1,408.00 |
| 99 | TSH | 004259 | TSH | 190 | 1 Day | \$5.00 | \$950.00 |
| | TSH 3rd Generation | 004259 | TSH | 1,302 | 1 Day | \$5.00 | \$6,510.00 |
| 101 | UA - Culture reflex | 377036 | UA/M with Culture Reflex | 2,359 | 1 Day | \$4.00 | \$9,436.00 |
| | Culture reflex @ additional cost | 008848 | Urine Culture, Routine **non-ord REFLEX TEST** | 1,188 | 3 days | \$7.00 | \$8,316.00 |
| | Uric Acid | 001057 | Uric Acid, Serum | 35 | 1 Day | \$2.75 | \$96.25 |
| | Urinalysis, complete | 003772 | Urinalysis, Complete | 3,952 | 1 Day | \$3.00 | \$11,856.00 |
| 105 | Valporic acid serum | 007260 | Valproic Acid (Depakote),S | 2,599 | 1 Day | \$10.00 | \$25,990.00 |
| 106 | Varicella-Zoster IGG | 096206 | Varicella-Zoster V Ab, IgG | 28 | 1 Day | \$12.00 | \$336.00 |
| 107 | Vitamin B-12 | 001503 | Vitamin B12 | 262 | 1 Day | \$6.50 | \$1,703.00 |
| 108 | Vitamin B-12 and Folates | 000810 | Vitamin B12 and Folate | 556 | 1 Day | \$12.00 | \$6,672.00 |

\$229,674 80

LabCorp has attempted to match a test code to each test or profile identified in this bid based on the written test descriptions provided If the specific test code is used in ordering the test, the price quoted will be in effect. If LabCorp has assigned an inaccurate test code due to its misunderstanding of your test description, or if the test configurations do not meet your needs for any reason, please contact your LabCorp sales representative or account manager immediately. We will review the test requirements and, if necessary, assign a more appropriate test code at a mutually agreeable price.

For the performance of tests not set forth above, LabCorp will offer the fees set forth in the price list current at the time the test is performed less an across-the-board discount of 50%, except for the tests listed in LabCorp's "Non-Discountable List", which will be performed at book price. LabCorp shall have the right to remove any test from the set price list and place it on the Non-Discountable List, in the event of a material change which affects the difficulty or cost of providing any test. Any other change in the fees reflected herein shall be effective following a 30-day written notice.

West Virginia Department of Health and Human Resources Bureau for Behavioral Health and Health Facilities Office of Health Facilities ---- Reference Laboratory Services BHS10009

EXHIBIT B

| В | HS10009 | | | COLUMN A | | COLUMN B | COLUMN C |
|------|--|--------|------------------------|---|---------------------|------------------|---------------|
| E | XHIBIT - B | | | | | | |
| | lost frequently ordred panels, rofiles, screens and cultures. | | | | | | |
| | em Description (Test) | Test# | LabCorp Description | Estimated Annual Volume of Tests | Turn Around Time | Cost Per Test | Total (A + B) |
| | riagnostic Multi Chem (28 Tests) | 306265 | CMP12+LP+6AC | 1,502 | 1 Day | \$8.45 | \$12,691.90 |
| | lbumin, Alkaline Phos | | | | | | |
| | LT-SGPT, AST-SGOT | | | | | | |
| | UN, BUN/Creatine | | | | | | |
| | alcium, Choride | | | | | | |
| | holesterol, Total, Creatine | | | | | | |
| | GT, Glucose, Iron, Total | | | | | | |
| 1_ | DH, Phospohorous, Potassium, | | | | | | <u> </u> |
| | odium, Bilirubin, Total | | | | | | |
| | rotein, Total, Triglycerides, | | | | | | <u> </u> |
| | lric Acid, HDL Cholesterol, | | | | | <u></u> | |
| | LDL Cholesterol, CAL, LDL Cholesterol, Calc | | | | | | |
| | . Choletersterol.HDL. Ratio | | | | | | |
| | stimate CHD Risk, Globulin, Total, | | | | | | |
| | /G Ratio | | | | | | |
| 16 | . O Trailo | | | | | | |
| | hyroid Profile includes (4 tests) | 000620 | Thyroid Panel With TSH | 1,208 | 1 Day | \$11.50 | \$13,892.00 |
| | SH (High Sensitivity, T3 Uptake) | | | | | | |
| | 4 Thyroxine, Free Thyroxine Index | | | 297 | | | |
| | | | | | | | |
| 20 E | lectrolyte Panel inclues (3 tests) | 000604 | CI+K+Na | 316 | 1 Day | \$2.95 | \$932.20 |
| | Sodium | | | | | | |
| 22 F | Potassium | | | | | | |
| 23 C | Chloride | | | | | | |
| | | | | | <u> </u> | | |
| | Drug Abuse Screen (seven) Urine, vithout confirmation | 071910 | Drug Screen (7) | 1,256 | 24-48 Hours | \$15.00 | \$18,840.00 |
| | mphetamine, Cocaine | | | | | | |
| | Barbiturates, Opiates | | | | | | |
| 27 E | Bensodiazepines, Phencyclidine | | | | | | |
| 28 C | Cannabinoid | | | | | | |
| 20 1 | IFP7 & 3AC | 000505 | HFP7+3AC | 455 | 1 Day | \$3.65 | \$1,660.75 |
| | Protein, Total(s), Alkaline Phosphatase (s) | 000000 | | | | | |
| | Albumin, (s), LDG, AST (SGOT), GTT | | | | | | |
| | Bilirubin, Total, Bilirubin, Direct | | | | <u> </u> | | |
| | Cholesterol, Total | | | | | | |
| | Cholesterol, Total | | | | | | |
| J4 C | Projected Or, Total | | | | | 1 | |

West Virginia Department of Health and Human Resources Bureau for Behavioral Health and Health Facilities Office of Health Facilities ---- Reference Laboratory Services BHS10009

EXHIBIT B

| BHS10009 | | | | COLUMN A | | COLUMN B | COLUMN C |
|---------------------------|---------------------------|--------|---|---|---------------------|------------------|--------------------------|
| EXHIBIT - B | | | | | | | |
| | y ordred panels, | | | | : | | |
| profiles, scree | ns and cultures. | | | | | | |
| Mana Danasiaki | on (Teat) | Test# | LabCorp Description | Estimated Annual Volume of Tests | Turn Around Time | Cost Per Test | Total (A+B) |
| Item Description | | 025254 | LP without LDL,VLDL | 5,327 | 1 Day | \$3.25 | \$17,312.75 |
| | our includes: (3 test) | 020204 | EF WILLIOUS EDE, VEDE | 0,321 | 1 Day | ψ5.20 | ψ17,012.70 |
| 36 Cholesterol, Tot | [al | | | | | | |
| 37 Triglycerides | | | <u> </u> | | | | |
| 38 HDL Cholestero |) | | | | | | |
| 1 1 1 | creen, Blood - without | 707550 | 767558 7 Blood-Scr (Only) | 831 | 24-48 Hours | \$151.88 | \$126,212.28 |
| 39 confirmation | | 767558 | 707556 7 Blood-Sci (Olly) | 031 | 24-40 Hours | ψ151.00 | Ψ120,212.20 |
| 40 Amphetamine, 0 | | | | | | | |
| 41 Barbiturates, Or | | | | | | | |
| 42 Benzodiazepine | es, Phencycline | | | | | | |
| 43 Cannabinoid | | | | | | | |
| | | | | | | <u> </u> | |
| Cultures: | | 400040 | Lower Respiratory Culture | 107 | 2 Dave | \$10.00 | \$1,070.00 |
| 44 Lower Respirato | | 180810 | | 107 | 2 Days | \$8.00 | \$768.00 |
| 45 Upper Respirato | | 008342 | Upper Respiratory Culture Aerobic Bacterial Culture | 96 | 1-2 Days | | |
| 46 General Bacteri | al Culture | 000010 | | 137 | 2-3 Days | \$10.00 | \$1,370.00 |
| 47 Blood Culture | | | Blood Culture, Routine | 842 | 5 Days | \$8.00 | \$6,736.00 \$1,650.00 |
| 48 Stool Culture | | | Stool Culture | 55 | 3 Days | \$30.00 | |
| 49 Urine Culture | | 008847 | Urine Culture, Routine | 1,306 | 1-2 Days | \$7.00 | \$9,142.00 |
| 50 Sputum Culture | | 180810 | Lower Respiratory Culture | 98 | 2 Days | \$10.00 | \$980.00 |
| 51 Sensitivity Orga | nism | S00001 | Sensitivity Organism #1 | 529 | 1 Day | \$5.00 | \$2,645.00 |
| | | | III Matela Drefila I Diagel | 04 | 4.0 | \$52.00 | \$1,113.00 |
| 52 Heavy Metal Pr | ofile (Blood) | 042580 | Heavy Metals Profile I, Blood | 21 | 1 Day | \$53.00 | \$1,113.00 |
| 53 Arsenic | | | | | | | |
| 54 Lead | | | | 1 | | | |
| 55 Mercury | | | | | | | |
| 56 Hepatitis Profil | le (Diagnostic follow-up) | 046938 | Hepatitis Follow-Up (Prof II) | 46 | 4 Days | \$20.00 | \$920.00 |
| 57 HBc Ag; anti-HE | | | | | | | |
| 58 anti-HBS; Interp | | | | | | | |
| | | | | | | | |
| 59 Hepatitis Profi | | 336408 | HBcAb+HBcigM+HBeAb+HBeAg+HB | 421 | 4 Days | \$46.00 | \$19,366.00 |
| | G; Anti-HBC, total | | | | | | |
| | anti-HBc; anti-HBs | | | | | | |
| 62 anti-HCV; interp | pretation | | | | | | |
| | | | LIAVILIDVI (OEl-VIII) | 10- | 4.5 | 050.50 | PC 704 50 |
| 63 Hepatitis Profil | | 058552 | HAV/HBV (Profile VII) | 107 | 1 Day | \$53.50 | \$5,724.50 |
| | anti HAV, Igm; HBs Ag; | | | | | | |
| 65 HBc Ag; anti-HE | 3C, total; anti-HBC, Igm; | | | | L | | |

CONFIDENTIAL

West Virginia Department of Health and Human Resources Bureau for Behavioral Health and Health Facilities Office of Health Facilities ---- Reference Laboratory Services BHS10009

EXHIBIT B

| | BHS10009 | | | COLUMN A | | COLUMN B | COLUMN C |
|----------|--|--------|---|---|---------------------|---------------------|---------------|
| | EXHIBIT - B | | | | | | |
| | Most frequently ordred panels, profiles, screens and cultures. | | | | | | |
| | ltem Description (Test) | Test # | LabCorp Description | Estimated Annual Volume of Tests | Turn Around Time | Cost Per Test | Total (A + B) |
| 66 | anti-HBc; anti-HBS; interpretation | | | | | | |
| | | | | | | | **** |
| 67 | Hepatitis A Profile | 028928 | Hepatitis A (Prof V) | 57 | 1-2 Days | \$14.50 | \$826.50 |
| 68 | Anti-HAV, total; anti-Hav, Igm | | | | | | |
| 69 | Interpretation | | | | | | |
| 70 | II | 058545 | Hepatitis B Virus (Profile VI) | 52 | 1 Day | \$39.00 | \$2,028.00 |
| 70 | Hepatitis B Profile | 000040 | ricpatitis D virus (1 tollic vi) | 32 | 1 Day | φοσισσ | Ψ2,020.00 |
| 71 | HBs Ag; HBc Ag; anti-Hbc, total | | | | | | |
| 72 | anti-HBC, Igm: anti-HBc anti-HBs, Interpretation | | | | | | |
| 73 | anti-nos, interpretation | | | | | | |
| 74 | Hepatitis C Virus Antibody | 140659 | Hep C Virus Ab | 416 | 1 Day | \$7.00 | \$2,912.00 |
| | Additional Send Outs: | | | | | | |
| 75 | 4 hr. GTT | 102004 | Gestational Glucose Tolerance | 6 | 1 Day | \$54.00 | \$324.00 |
| 76 | Albumin | | Albumin, Serum | 129 | 1 Day | \$2.75 | \$354.75 |
| 77 | Alkaline phos panel | | Alkaline Phosphatase, Serum | 2 | 1 Day | \$2.75 | \$5.50 |
| 78 | ALT | 001545 | ALT (SGPT) | 112 | 1 Day | \$2.75 | \$308.00 |
| 79 | ALT - SGOT | 001123 | AST (SGOT) | 29 | 1 Day | \$2.75 | \$79.75 |
| 80 | ALT - SGPT | 001545 | ALT (SGPT) | 23 | 1 Day | \$2.75 | \$63.25 |
| 81 | Amiodarone | 706705 | AMIODARONE (CORDARONE), SERUM | 4 | 1 Day | \$70.50 | \$282.00 |
| 82 | ANC | 162388 | Antineutrophil Cytoplasmic Ab | 80 | 1-2 Days | \$18.00 | \$1,440.00 |
| 83 | AST | | AST (SGOT) | 146 | 1 Day | \$2.75 | \$401.50 |
| 84 | Basic Metabolic Panel | • | Basic Metabolic Panel (8) | 70 | 1 Day | \$3.45 | |
| 85 | B-Type Natriuretic Peptide | | B-Type Natriuretic Peptide | 96 | 5 Days | \$35.00 | |
| | ВМР | 1 | Basic Metabolic Panel (8) | 188 | 1 Day | \$3.45 | |
| 87 | CA125 | 002303 | Cancer Antigen (CA) 125 | 4 | 5 Days | \$10.00 | |
| 88 | CBC | 005009 | CBC With Differential/Platelet | 70 | 1 Day | \$3.00 | |
| 89 | Chloride | | Chloride, Serum | 86 | 1 Day | \$2.75 | |
| 90 | Cholesterol, Total | | Cholesterol, Total | 6 | 1 Day | \$2.75 | |
| 91 | Comp Metabolic Panel 13 | | Comp. Metabolic Panel (13) | 47 | 1 Day | \$3.95 | <u> </u> |
| 92 | Comp Metabolic Panel 14 | 322000 | Comp. Metabolic Panel (14) | 214 | 1 Day | \$4.05 | |
| 93 | CPK | 001362 | Creatine Kinase, Total, Serum | 24 | 1 Day | \$2.75 | |
| 94 | Creatine | 002402 | Creatine, Serum | 15 | 1 Day | \$20.13 \$125.00 | |
| 95 | Cystic Fibrosis Profile | | Cystic Fibrosis Profile Valproic Acid (Depakote),S | 80 | 7 Days | \$125.00 | \$10,000.00 |
| 96 | Depakote | | Phenytoin (Dilantin), Serum | 60 | 1 Day | \$10.00 | \$200.00 |
| 97 | Dilantin | | Thyroxine (T4) Free, Direct, S | 20 | 1 Day | \$10.00 | |
| 98 99 | Free T4 FSH | | FSH, Serum | 598 50 | 1 Day 1 Day | \$9.00 | |

CONFIDENTIAL

West Virginia Department of Health and Human Resources Bureau for Behavioral Health and Health Facilities Office of Health Facilities ---- Reference Laboratory Services BHS10009

EXHIBIT B

| | BHS10009 | | | COLUMN A | | COLUMN B | COLUMN C |
|-----|--|--------|--------------------------------|---|---------------------|------------------|--------------|
| *** | EXHIBIT - B | | | | | | |
| | Most frequently ordred panels, profiles, screens and cultures. | | | | | | |
| | Item Description (Test) | Test# | LabCorp Description | Estimated Annual Volume of Tests | Turn Around Time | Cost Per Test | Total (A+B) |
| 100 | FSH and LH | 028480 | FSH and LH | 48 | 1 Day | \$18.00 | \$864.00 |
| 101 | Gentamiacin | 007161 | Gentamicin Random, Serum | 2 | 1 Day | \$45.00 | \$90.00 |
| 102 | GGT | 001958 | GGT | 3 | 1 Day | \$2.75 | \$8.25 |
| 103 | H&H | 031088 | HGB+HCT | 4 | 1 Day | \$12.38 | \$49.52 |
| 104 | Hematocrit | 005058 | Hematocrit | 10 | 1 Day | \$2.85 | \$28.50 |
| 105 | Hemoglobin | | Hemoglobin | 10 | 1 Day | \$2.85 | \$28.50 |
| 106 | HSV culture | 186072 | HSV Culture Without Typing | 3 | 3 Days | \$112.50 | \$337.50 |
| 107 | INR | 005199 | Prothrombin Time (PT) | 24 | 1 Day | \$3.00 | \$72.00 |
| 108 | Ldh | 001115 | LDH | 4 | 1 Day | \$2.75 | \$11.00 |
| 109 | LFT | 322755 | Hepatic Function Panel (7) | 45 | 1 Day | \$3.35 | \$150.75 |
| 110 | Mumps IgG | | Mumps Antibodies, IgG | 3 | 2-3 Days | \$15.00 | \$45.00 |
| 111 | PAP (Thin Prep) | 192005 | Gynecologic Mono-layer Pap | 478 | 5 Days | \$24.00 | \$11,472.00 |
| 112 | Pro BNP | 143000 | proBNP | 20 | 3 Days | \$136.50 | \$2,730.00 |
| 113 | Progesterone | 004317 | Progesterone | 25 | 1 Day | \$9.00 | \$225.00 |
| 114 | PTH (intact) | 015610 | PTH, Intact | 119 | 1 Day | \$10.00 | \$1,190.00 |
| 115 | RA Panel | 006502 | Rheumatoid Arthritis Factor | 56 | 1 Day | \$4.50 | \$252.00 |
| 116 | Renal Panel | 322777 | Renal Panel (10) | 165 | 1 Day | \$3.65 | \$602.25 |
| 117 | Rheumatoid Arthritis Factor | 006502 | Rheumatoid Arthritis Factor | 60 | 1 Day | \$4.50 | \$270.00 |
| 118 | Rubeola 1Gg | 096560 | Rubeola Antibodies, IgG | 4 | 1 Day | \$15.00 | \$60.00 |
| 119 | Teanetal level | NMI | #N/A | 2 | | | |
| 120 | Tegetrol | 007419 | Carbamazepine(Tegretol), Serum | 2 | 1 Day | \$10.00 | \$20.00 |
| 121 | Vitamin B12 and Folate | 000810 | Vitamin B12 and Folate | 180 | 1 Day | \$12.00 | \$2,160.00 |
| 122 | Vit. D, 1-125 Dihydroxy | 081091 | Vitamin D, 1,25 Dihydroxy | 98 | 2 Days | \$25.00 | \$2,450.00 |
| 123 | Vit. D, -25- hydroxyl | 081950 | Vitamin D, 25-Hydroxy | 2 | 1 Day | \$18.00 | \$36.00 |
| 124 | WBC | 005025 | White Blood Cell (WBC) Count | 508 | 1 Day | \$2.85 | \$1,447.80 |
| | | | | | Total of Exhibi | t B - Bid Sheet | \$297,065.10 |

| _ | |
|--------------------------------|--------------|
| Total of Exhibit A - Bid Sheet | \$229,674.80 |
| Total of Exhibit B - Bid Sheet | \$297,065.10 |
| Grand Total = Exhibit A + B | \$526,739.90 |

LabCorp has attempted to match a test code to each test or profile identified in this bid based on the written test descriptions provided. If the specific test code is used in ordering the test, the price quoted will be in effect. If LabCorp has assigned an inaccurate test code due to its misunderstanding of your test description, or if the test configurations do not meet your needs for any reason, please contact your LabCorp sales representative or account manager immediately. We will review the test requirements and, if necessary, assign a more appropriate test code at a mutually agreeable price.

For the performance of tests not set forth above, LabCorp will offer the fees set forth in the price list current at the time the test is performed less an across-the-board discount of 50%, except for the tests listed in LabCorp's "Non-Discountable List", which will be performed at book price LabCorp shall have the right to remove any test from the set price list and place it on the Non-Discountable List, in the event of a material change which affects the difficulty or cost of providing any test. Any other change in the fees reflected herein shall be effective following a 30-day written notice.

CONFIDENTIAL

West Virginia Department of Health and Human Resources Bureau for Behavioral Health and Health Facilities Office of Health Facilities ---- Reference Laboratory Services BHS10009

EXHIBIT B

| BHS10009 | | | COLUMN A | | COLUMN B | COLUMN C |
|--|--------|---------------------|---|-------------|------------------|---------------|
| EXHIBIT - B | | | | | | |
| Most frequently ordred panels, profiles, screens and cultures. | | | | | | |
| Item Description (Test) | Test # | LabCorp Description | Estimated Annual Volume of Tests | Turn Around | Cost Per Test | Total (A + B) |

EXHIBIT C (Vendor's Attachment of Phlebotomy Services Offered)

| | Types & Descriptions of Phlebotomy Services Offered |
|---|---|
| 1 | LabCorp will work with the current phlebotomy arrangement at each facility to maintain the service level. |
| 2 | |
| 3 | |

ALERT result call designation form

Please complete this form, Fold, insert into the Business reply envelope, And mail to LabCorp

Thank you!



ALERT result call designation form 2 of 9 ALERT result call designation form 1of 5

After you have reviewed this information, please sign and return the completed ALERT result call designation form verifying your selected ALERT results tests and values to LabCorp in the return envelope

Note: LabCorp will only call ALERT tests and values if indicated below by the client. Notification of ALERT results will occur on weekdays, Monday through Friday, during normal business hours

| Please check the appropriate box: | |
|---|------|
| \square Call all of the following default ALERT results | |
| Call only the selected ALERT results with the indicated values. (Also enter new values for each test chosen if you desire notification at levels differ than the default values) | rent |

| Call as Alert (∜) | Test | Units | Referenc e Interval | Defaul t call Low <u><:</u> | Defaul t call High | Call at Default Level | Change LOW to: | Change HIGH to: |
|----------------------------|-----------------------------------|--------|------------------------|--------------------------------------|--------------------------|-----------------------------|----------------------|-----------------------|
| | ACE | U/L | 12 – 68 | | 100 | | | |
| | ACTH Plasma | pgml | 6 – 48 | | 1000 | | | |
| | Albumin CSF | mg/dL | 11 - 48 | | 1000 | | | |
| | Albumin Serum | g/dL | 35-55 | 2 | 6 | | | |
| | Aldolase | U/L | 12-76 | | 67 | | | |
| | ALT (SGPT) | IU/L | 0- 40 | | 500 | | | |
| | AST (SGOT) | IU/L | 0 - 40 | | 500 | | | |
| | Alkaline Phosphatase | IU/L | (M) 25-160 | | 1000 | | | |
| | | | (F) 25- 165 | | | | | |
| | Alpha-1- Antitrypsin Serum | mg/dL | 90 - 200 | | 500 | | | |
| | Ammonia | ug/dL | 19 - 102 | | 120 | | | |
| | Amylase | U/L | 0 - 99 | 5 | 400 | | | |
| | Bile Acid Total | umol/L | 4.5 - 24.6 | | 10000 | | | |
| | Bilirubin Direct | mg/dL | 00-04 | | 10 | | | |
| | Bilirubin, Total | mg/dL | 01-12 | 0 | 12 | | | |
| | Carnitine, Free | umol/L | 16 - 60 | 10 | 200 | | | |
| | Carnitine, Total | umol/L | 25 - 69 | 10 | 200 | | | |
| | Cholesterol, Total | mg/dL | 100 – 199 | | 600 | | | |
| | Chloride Serum | mmol/L | 96 - 109 | 75 | 115 | | | |
| | CO ₂ Total Content | mmol/L | 20 - 32 | 10 | 40 | | | |
| | Complement C3 Serum Adult | mgdL | 90 – 180 | 40 | 300 | | | |
| | Complement C4 Serum Adult | mgdL | 9 – 36 | | 500 | | | |
| | Complement, Total (CH50) Adult | mgdL | 22 – 60 | 10 | 500 | | | |
| | Creatinine, Serum | mg/dL | 05-15 | | 15 | | | |
| | Creatine Kinase, MB | ng/mL | 00-33 | | 3,4 | | | |

ALERT result call designation form 3 of 9

| Call as Alert | Test | Units | Referenc e Interval | Defaul t call Low <u><:</u> | Defaul t call High | Call at Default Level | Change LOW to: | Change HIGH to: |
|---------------------|---|----------------|--|--------------------------------------|--------------------------|-----------------------|----------------------|-----------------------|
| | Creatine Kinase, Total Serum | U/L | 24 - 204 | | 500 | | | |
| | Cystathionine, Serum | nmol/L | 44 – 342 | | 2500 | | | |
| | Factors II Activity | % | 75 - 130 | 5 | 500 | | | |
| | Factors V Activity | % | 60 - 140 | 5 | 500 | | | |
| | Factors VII Activity | % | 50 - 150 | 5 | 500 | | | |
| | Factors VIII Activity | % | 50 - 150 | 5 | 500 | | | |
| | Factors IX Activity | % | 55 - 150 | 5 | 500 | | | |
| | Factors X Activity | % | 65 - 140 | 5 | 500 | | | |
| | Factors XI Activity | % | 60-135 | 5 | 500 | | | |
| | Factors XII Activity | % | 50 - 150 | 5 | 500 | | | |
| | Fibrinogen Activity | mg/dL | 193- 423 | 100 | 800 | | | |
| | Glucose, CSF | mg/dL | 30 -70 | 30 | 400 | | | |
| | Glucose, Gestational:1st Trimester FBS | mg/dL | 65 - 95 | 40 | 96 | | | |
| | Glucose, Gestational:1st Trimester 1-hour | mg/dL | 65-180 | 40 | 181 | | | |
| | Glucose, Gestational:1st Trimester 2-hour | mg/dL | 65-155 | 40 | 156 | | | |
| | Glucose, Gestational:1st Trimester 3-hour | mg/dL | 65-140 | 40 | 141 | | | |
| | Gamma- glutamylTranspeptidase | IU/L | (M) 0 - 65 (F) 0 - 60 | | 650 | | | |
| | Haptoglobin | m/dL | 34 – 200 | | 450 | | | |
| | Hemoglobin | g/dL | (M) 12.5 – 17.0 (F) 11.5 – 15.0 | 7 | 20 | | | |
| | Histamine Determination Urine | ug/24 Hours | 13 – 62 | 13 | 63 | | | |
| | (LD) Fraction 1 | % | 16 - 35 | | 100 | | | |
| | (LD) Fraction 2 | % | 24 - 41 | | 100 | | | |
| | (LD) Fraction 3 | % | 16 - 27 | | 100 | | | |
| | (LD) Fraction 4 | % | 5 - 14 | | 100 | | | |
| | (LD) Fraction 5 | % | 5 -24 | | 100 | | | |
| | Iron-binding Capacity | ug/dL | 250 - 450 | 125 | 550 | | | |
| | Iron, Serum | ug/dL | (M) 40 – 155 | 10 | 260 | | | |
| | | | (F) 35 - 155 | | | | | |

ALERT result call designation form 4 of 9

| Cali as Alert (∀) | Test. | Units | Referenc e interval | Defaul t call Low <u><:</u> | Defaul t call High ≥: | Call at Default Level | Change LOW to: | Ghange HIGH to: |
|----------------------------|---|-----------|--|--------------------------------------|--------------------------------|-----------------------------|----------------------|-----------------------|
| | Iron, Saturation | % | 15 - 55 | 10 | 75 | | | |
| | lonized Calcium | mg/dL | 4.5 – 5.6 | 3 | 65 | | | |
| | Lactic Acid Plasma | mg/dL | 4 5 – 19 8 | | 30 | | | |
| | Lead Blood Adult | ug/dL | 0 - 19 | | 29 | | | |
| | Lead, Blood, Pediatric | ug/dL | 0 - 9 | | 19 | | | |
| | LDH | IU/L | 100 - 250 | 35 | 1000 | | | |
| | Magnesium | mg/dL | 16-26 | 1 | 35 | | | |
| | Neutrophil (Absolute) | x10³/uL | 1.8-7.8 | 1 | 10 | | | |
| | Osmolality Serum | mOsmol/kg | 275 - 301 | 230 | 375 | | | |
| | pH Urine | | 4.5 80 | 4 | 10 | | | |
| | Phosphorus | mg/dL | 2.5 – 4.5 | 1 | 9 | | | |
| | Platelet Count | x10³/uL | 140 - 415 | 100 | 800 | | | |
| | Partial Thromboplastin Time (PTT), Activated | seconds | 22 - 36 | | 60 | | | |
| | Phospholipids, Serum | mg/dL | 150 250 | | 4000 | | | |
| | Protein Total, CSF | mg/dL | 13 0 – 40.0 | | 150 | | | |
| | Protein Total Serum | g/dL | 60-85 | 4 5 | 10 | | | |
| | RBC | x10⁵/uL | (M) 4.10 – 5.60 (F) 3.80 – 5.10 | 2 75 | 7 | | | |
| | Serotonin, Serum | ng/mL | 0 – 420 | | 500 | | | |
| | Trilodothyronine Free, Serum | pg/mL | 23-42 | | 20 | | | |
| | Thyroxine (T4) | ug/dL | 4 5 – 12 0 | 2 | 18 | | | |
| | Total Bilirubin | mg/dL | 01-12 | 0 | 12 | | | |
| | Urea Nitrogen Serum (BUN) | mg/dL | 5 – 26 | 2 | 75 | | | |
| | Uric Acid, Serum | mg/dL | 24-82 | | 15 | | | |
| | Vitamin C | mg/dL | 04-20 | 0 1 | 5 | | | |
| | WBC | x10³/uL | 40-105 | 2 5 | 20 | | | |
| | | | Toxicol | ogy | | | | |
| | Acetaminophen Serum | ug/mL | 10 - 25 | | 200 | | | |
| | Aluminum, Plasma/Serum | ug/L | 0 - 9 | | 60 | | | |
| | Amikacin, Trough Serum | ug/mL | 1.0 - 8.0 | | 8 | | | |
| | Amikacin, Peak, Serum | ug/mL | 20.0 30 0 | | 30 | | | |
| | Amiodarone | ug/mL | 10-25 | | 10 | | | |
| | Noramiodarone (Desethyl [®]) | ug/mL | 10-25 | | 10 | | | |
| | Amitriptyline + Nortriptyline | ng/mL | 120-250 | | 500 | | | |

ALERT result call designation form 5 of 9

| Call | Test | Units | Referenc | Defaul | Defaul | Call at | Change | Change |
|--------------------|--|--------|------------------|----------------------------|----------------|------------------|------------|-------------|
| as Alert (√) | | | e Interval | t call Low <u><:</u> | t call High | Default Level | LOW to: | HIGH to: |
| | Amobarbital (Amytal [®]) | ug/mL | 5 – 15 | | 15 | | | |
| | Antimony, Urine | ug/L | 0 – 9 | | 1000 | | | |
| | Arsenic Blood | ug/L | 2 - 23 | | 100 | | | |
| | Arsenic (Total). Urine | ug/L | 0 – 50 | | 1000 | | · | |
| | Arsenic (Inorganic) Urine | ug/L | 0 – 19 | | 250 | | | |
| | Butalbital | ug/mL | 1 – 10 | | 15 | | | |
| | Cadmium Blood | ug/L | 0.0 – 1.2 | | 15 | | | |
| | Caffeine | ug/mL | 30-150 | | 50 | | | |
| | Carbamazepine | ug/mL | 4.0 – 12.0 | | 12 1 | | | |
| | Carbamazepine, Free,Serum | Ug/ml. | 06-42 | | 4 2 | | | |
| | Chlordiazepoxide | ug/mL | 01-09 | | 5 | | | |
| | Norchlordiazepoxide | ug/mL | 01-06 | | 5 | | | |
| | Nordiazepam | ug/mL | 01-1.4 | | 5 | | | |
| | Chlorpromazine | ng/mL | 30 – 300 | | 750 | | | |
| | Clomipramine | ng/mL | 70 – 200 | | 400 | | | |
| | Norclomipramine (Desmethyl®) | ng/mL | 150 – 300 | | 600 | | | |
| | Clonazepam | ng/mL | 15 – 60 | | 80 | | | |
| | Clorazepate (Tranxene) Serum | ug/mL | 05-20 | | 5 | | | |
| | Copper, Serum | ug/di | 70 – 155 | | 500 | | | |
| | Cyclosporine, Blood | ng/mL | 100 – 400 | | 450 | | | |
| | Desipramine | ng/mL | 150 – 250 | | 500 | | | |
| | Diazepam + Nordiazepam | ng/mL | 01-25 | | 5 | | | |
| | Disopyramide (Norpace [®]) | ug/mL | 20-5.0 | | 5 | | | |
| | Doxepin + Desmethyldoxepin | ng/mL | 150-250 | | 500 | | | |
| | Ethchlorvynol | ug/mL | 2 – 8 | | 13 | | | |
| | Ethosuximide | ug/mL | 40-100 | | 100 | | | |
| | Ethylene Glycol Serum | mg/dL | None detected | | 100 | | | |
| | Flecainide, Serum | ug/mL | 0.20 –1 00 | | 1 | | | |
| | Fluoxetine(Prozac®) | ng/mL | 91 – 302 | | 1000 | | | |
| | Fluphenazine (Prolixin [®]) | ng/mL | 03-40 | | 25 | | | |
| | Gabapentin | ug/mL | 4 0 – 16 0 | | 24 | | | |
| | Gentamicin, Trough, Serum | ug/mL | 05-15 | | 2 | | | |
| | Gentamicin, Peak Serum | ug/mL | 60-100 | | 12 | | | |

ALERT result call designation form 6 of 9

| Call as Alert (√) | Test | Units | Referenc e Interval | Defaul t call Low <u><:</u> | Defaul t call High >: | Call at Default Level | Change LOW to: | Change HIGH to: |
|---|---|--------------------|------------------------|--------------------------------------|--------------------------------|-----------------------------|----------------------|-----------------------|
| 200400000000000000000000000000000000000 | Gentamicin Random | ug/mL | 0 5 – 10.0 | | 12 | | | |
| | Haloperidol Serum | ng/mL | 4 – 26 | | 50 | | | |
| | Glutethimide | ug/mL | 20-6.0 | | 50 | | | |
| | Imipramine + Desipramine | ng/mL | 150-250 | | 500 | | | |
| | Lamotrigine Serum | ug/mL | 2 0 – 20 0 | | 20 | | | |
| | Levetiracetam, Serum | ug/mL | 50-630 | 4.9 | 63.1 | | | |
| | Lidocaine | ug/mL | 15-50 | | 5 | | | |
| | Lithium (Eskalith) Serum | mmol/L | 06-14 | | 15 | | | |
| | Magnesium, Urine 24 hr | mg/24 hours | 12 - 293 | | 1833 | | | |
| | Mandelic Acid Urine | mg/L | 0 5 | | 800 | | | |
| | Mandelic Acid/Creatinine Ratio | mg/g Стеаtinine | 0 – 800 | | 800 | | | |
| | Meperidine | ng/mL | 70-500 | | 1000 | | | |
| | Mephobarbital ,Serum | ug/mL | 8 – 15 | | 40 | | | |
| | Meprobamate | ug/mL | 60-120 | | 60 | | | |
| | Mercury Blood | ug/L | 0 0-149 | | 50 | | | |
| | Mercury/Creatinine Ratio | ug/g Creatinine | 0-5 | | 100 | | | |
| | Mercury Urine 24-hour | ug/24- hour | 0 - 20 | | 100 | | | |
| | Methadone | ng/mL | 100 – 400 | | 2000 | | | |
| | Methotrexate | umol/L | 0 02 – 5 00 | | 5 | | | |
| | Methylmalonic Acid, Serum | nmol/L | 73-376 | | 5000 | | | |
| | Mexiletine (Mexitil [®]),Serum | ug/mL | 0 75 – 2.00 | | 2 | | | |
| | Mycophenolic Acid | ug/mL | 10-35 | | 41 | | | |
| | Nortriptylline | ng/mL | 50 – 150 | | 500 | | | |
| | Pentobarbital, Serum | ug/mL | 1 – 5 | | 8 | | | |
| | Phenobarbital | ug/mL | 15 – 40 | | 40 | | | |
| | Phenol (Total) | mg/L | 00-199 | | 49 9 | | | |
| | Phenol/Creatinine Ratio | mg/g Creatinine | 0 – 49 9 | | 49 9 | | | |
| | Phenytoin | ug/mL | 10 0 – 20.0 | | 20 | | | |
| | Phenytoin Free Serum | ug/mL | 10-20 | | 2 | | | |
| | Prazepam | ug/mL | 01-03 | | 5 | | | |
| | Primidone serum | ug/mL | 5.0-12.0 | | 12 | | | |
| | Procainamide | ug/mL | 4.0 – 10 0 | | 10 | | | |
| | Procainamide + NAPA | ug/mL | 10 0 - 30 0 | | 30 | | • | |

ALERT result call designation form 7 of 9

| Call as Alert | Test | Units | Referenc e Interval | Defaul t call Low <u><:</u> | Defaul t call High | Call at Default Level | Change LOW to: | Change HIGH to: |
|---------------------|--|--------|------------------------|--------------------------------------|--------------------------|-----------------------------|----------------------|-----------------------|
| (v) | Propoxyphene, Serum | ng/mL | 100-400 | | <u>>:</u> 500 | | | |
| | Protoporphyrin (FEP), Adult & Pediatric | ug/L | 0 - 34 | | 200 | | | |
| | Zinc Protoporphyrin Adult & Pediatric | ug/dL | 0 - 38 | | 200 | | | |
| | Quinidine | ug/mL | 20-5.0 | | 5 | | | |
| | Risperidone + 9-OH | ng/mL | 10 – 120 | | 150 | | | |
| | Salicylate, Serum | ug/mL | 30 – 250 | | 300 | | | |
| | Secobarbital, Serum | ug/mL | 1 – 5 | | 10 | | | |
| | Selenium, Blood | ug/L | 100 – 340 | 20 | 600 | | | |
| | Sirolimus | ng/mL | 3 0 – 20.0 | | 40 | | | |
| | Tacrolimus, Blood | ng/mL | 2 0 – 20 0 | | 20 1 | | | |
| | Theophylline Adult | ug/mL | 10.0-20.0 | | 20 | | | |
| | Theophylline, Neonatal | ug/mL | 5 0 10 0 | | 10 | | | |
| | Tobramycin, Trough Serum | ug/mL | 05-15 | | 2 | | | ···· |
| | Tobramycin, Peak, Serum | ug/mL | 60-100 | | 12 | | | |
| | Trazodone (Desyrel®) | ug/mL | 0.8 – 16 | | 5 | | | |
| | Valproic Acid (Depakote®) | ug/mL | 50 - 120 | | 120 | | | |
| | Valproic Acid, Free Serum | ug/mL | 4 0 – 12 0 | | 12 | | | |
| | Vancomycin, Trough Serum | ug/mL | 5 0 – 10 0 | | 20 | | | |
| | Vancomycin, Peak, Serum | ug/ml. | 25.0 40 0 | | 41 | | | • |
| | Warfarin (Coumadin [®]) | ug/mL | 10-100 | | 10 | | | |

ALERT result call designation form 8 of 9

Alpha or Qualitative ALERT Results (results that are not numbers)

LabCorp will continue to call qualitative ALERT results as soon as they are resulted and verified, Monday through Friday, 8:00 AM to 5:00 PM; however, for cytology and histology, you can request calls for low-grade lesions and/or suspicious results

| Call as Alert | Test | Abnormal Result | Call at Default Level |
|---|--|--|------------------------|
| | Cytology and Histology Tests | Abnormal Results | Special Request(s) |
| Х | Pap Smear | High-grade squamous intraepithelial lesions (HSIL) or malignant | |
| | Nongynecological Specimens | All positive and highly suspicious specimens or specially requested call reports | |
| X | Tissue Analysis | Malignancy | |
| | Microbiology Test | Abnormal Results | |
| X | Acid-fast Bacilli Stains and Cultures | Positive smear and/or culture | Unavailable for Change |
| X training 1 S Allain College 1 Page | Stool Cultures | Positive For: Salmonella, Shigella, Campylobacter, Yersinia (special culture) Vibro (special culture) and enterohemorrhagic <i>E. coli</i> | Unavailable for Change |
| X | Cryptococcal Antigen, Serum and CSF | Positive | Unavailable for Change |
| X | Strep pneumoniae Antigen | Positive | Unavailable for Change |
| X | Haemophilus influenzae, B Antigen | Positive | Unavailable for Change |
| X | Neisseria meningitidis Antigen | Positive | Unavailable for Change |
| <u>-</u> | Other Test | Abnormal Results | |
| X | Blood Smear | Presence of malarial parasites | Unavailable for Change |
| X | L/S Ratio (Amniotic Fluid) | All results | Unavailable for Change |
| Xerose | Amniotic Scan for Bilirubin | All results | Unavailable for Change |

ALERT result call designation form 9 of 9 Special physician or client-specific ALERT limits

| I, ALERT resu that I deem to | Its. Based on my medical jobe ALERT results. | _, have been advised o udgment, I request that | f the LabCorp policy c I be called for the foll | oncerning notification of owing additional results |
|------------------------------------|---|--|--|---|
| Other specific | c ALERT results to call: | | | |
| Individual Te | | Test Number | Low Limit | High Limit |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| changes in carepresentativ | ame all responsibility for the alling instructions and here es from any and all claims a listed ALERT results and | by agree to indemnify L or lawsuits resulting for contact procedures | abCorp and its emplom LabCorp's complia | yees and |
| - - - | Must be signe | ed by the physician(s) | | |
| Account Nu | mbers | | Contact/Phone Nu | mber(s): |
| | | | | |

CENTERS FOR MEDICARE & MEDICAID SERVICES CLINICAL LABORATORY IMPROVEMENT AMENDMENTS CERTIFICATE OF ACCREDITATION

LABORATORY NAME AND ADDRESS

36D0327333

LABORATORY CORPORATION OF AMERICA 6370 WILCOX ROAD DUBLIN, OH 43016

06/14/2009

LABORATORY DIRECTOR MODINA THRASHER MD

EXPIRATION DATE 06/13/2011

Pursuant to Section 353 of the Public He ith Services Act (42 U.S.C. 263a) as revised by the Clinical Laboratory Improvement Amendments (C1.1A), the above named laboratory located at the address shown hereon (and other approved locations) may accept human specimens for the purposes of performing laboratory examinations or procedures.

This certificant shall be valid until the expiration date above, but is subject to revocation, suspension, limitation, or other sanctions for violation of the Act or the regulations promulgated thereunder.

Furtith 4

Judith A. Yost, Director Division of Laboratory Services Survey and Certification Group Center for Medicaid and State Operations

CIVIS/

160 certs2 051609

ter for the first of the design of the Capital Capita Capital Capital Capital Capital Capital Capital Capital Capital

If you currently hold a Certificate of Compliance or Certificate of Accreditation, below is a list of the laboratory specialtics/subspecialties you are certified to perform and their effective date:

| LAB CERTIFICATION (CODE) BACTERIOLOGY (110) MYCOBACTERIOLOGY (115) MYCOLOGY (120) PARASITOLOGY (130) VIROLOGY (140) SYPHILIS SEROLOGY (210) GENERAL IMMUNOLOGY (220) ROUTINE CHEMISTRY (310) URINALYSIS (320) ENDOCRINOLOGY (330) TOXICOLOGY (340) HEMATOLOGY (400) ABO & RH GROUP (510) | 06/14/1995 06/14/1995 06/14/1995 06/14/1995 06/14/1995 06/14/1995 06/14/1995 06/14/1995 06/14/1995 06/14/1995 06/14/1995 06/14/1995 | I.AB CERTIFICATION (CODE) ANTIBODY TRANSFUSION (520) ANTIBODY NON-TRANSFUSION (530) ANTIBODY IDENTIFICATION (540) | 06/14/1995 06/14/1995 06/14/1995 06/14/1995 |
|---|--|--|--|
|---|--|--|--|

FOR MORE INFORMATION ABOUT CLIA, VISIT OUR WEBSITE AT WWW.CMS HHS.GOV/CLIA OR CONTACT YOUR LOCAL STATE AGENCY. PLEASE SEE THE REVERSE FOR YOUR STATE AGENCY'S ADDRESS AND PHONE NUMBER.
PLEASE CONTACT YOUR STATE AGENCY FOR ANY CHANGES TO YOUR CURRENT CERTIFICATE.



Laboratory Accredited



The College of American Pathologists

certifies that the laboratory named below

Laboratory Corporation of America Modina R. Thrasher, MD Dublin, Ohio

LAP Number: 1635001

AU-ID: 1182090

CLIA Number: 36D0327333

Laboratory Accreditation Program. Reinspection should occur prior is hereby fully accredited by the College of American Pathologists' has met all applicable standards for accreditation and to September 20, 2009 to maintain accreditation.

Accreditation does not automatically survive a change in director, ownership, or location and assumes that all interim requirements are met.

Hew Willow, or

President, College of American Pathologists Thomas Sodeman mo Frank Chair, Commission on Laboratory Accreditation



CLIENT SUPPLY REQUISITION

(COLUMBUS BRANCH)

PHONE: 614-889-1061 ext. 3310

FAX: 614-889-0870

DATE REQUESTED:

REQUESTED BY:

Date and Time of Delivery: ____

Account Number:

Account Name;

Account Address:

Phone Number:

| DESCRIPTION | QUANTITY ORDERED | UNIT | QUANTITY ISSUED | DESCRIPTION | QUANTITY ORDERED | UNIT | QUANTITY ISSUED |
|--|---------------------|------|--------------------|--|---------------------|--------|--------------------|
| EVACUATED BLOOD COLLECTION TUBES | | | | FORMS | | | |
| Serum Separator Tube 3.5 ml 3.5 ml | | Each | | Clinical Requisition | | Each | |
| Lavender Top (EDTA) 3 ml 4 ml | | Each | | Cytology/Histology Requisition | | Each | |
| Grey Top (Sodium Fluoride/Potassium Oxalate) 4 ml 🗌 6 ml 🗌 | | Each | | Chain of Custody (non NIDA) | | Each | |
| Grey Top, Glass (For Drug Screens & Volatiles) 5 ml | | Each | | LCM Requisition 8 Label 3x) 6 Label 2x) | | Pack | |
| Blue Top (Sodium Citrate) 2.7 ml [(For PT/PTT) 4.5 ml [| | Each | | LCM Laser Report Paper | | Pack | |
| Yellow Top (ACD) 6 ml 3.5 ml | | Each | | Supply Requisition Form | | Each | |
| Red Top (Plain) 3 ml 5 ml 10 ml | | Each | | Universal Report Paper 1 ply 2 ply 3 ply | | Вох | |
| Dark Blue Sodium Heparin 🗌 | | Each | | Printer Ribbon/Toner Cartridge | | Each | |
| Green Top (Sodium Heparin) 5 ml 10 ml | | Each | | Cartridge # | | | |
| Green Top (Lithium Heparin) 7 ml | | Each | | Specimen Log Book | | Each | |
| Microtainer Specify Type Lav. Plain Amber SST | | Each | | ABN Forms | | Each | |
| PPT 5 ml 🗌 | | Each | | | | | |
| | | | | | | | |
| | | | | CYTOLOGY/HISTOLOGY SUPPLIES | | | |
| BLOOD COLLECTION NEEDLES | | | | Pap Pack w/Brush | | Вох | |
| Needles (Multisample) 21G 1.25" | | Each | | Spray Fixative | | Bottle | |
| 22G 1.25" 🗍 | | Each | | Histology Micheles Media | | Each | |
| Needle Holder Regular Pediatric | | Each | | Biopsy Bottle w/Formalin 40 ml 120 ml | | Each | |
| | | | | ThinPrep Collectors | | Pack | |
| | | | | ThinPrep Vials | | Pack | |
| URINE COLLECTION | | | | Cyto- Spatulas Brushes Brooms | | Each | |
| Urinalysis Tube - Speckled Top | | Each | | AutoCyte | | Each | |
| C&S Urine Tube Grey Top | | Each | | Tripath Collection w/Rovers Blue Brooms | | Each | |
| Urine Transfer Straw | | Each | | | | 200.0 | |
| Cup, Paper "Urine Collection" | | Each | | | | | |
| 24 Hr. Urine Jug Boric Plain HCL Other | | Each | f | TRANSPORT MEDIA | | | |
| | | | | DNA Gen-Probe Male 🗌 Female 🗍 | | Each | |
| | " | | | Vira Pap HPV Digene | Ì | Each | |
| TRANSPORT MATERIAL | | | | OVA and Parasite Kit | | Each | |
| Transfer Tubes and Caps | | Each | | Stool C&S Vials | | Each | |
| LabCorp Specimen Bags 14×22 in. | | Each | | Para-Pak Ciean Vials | | Each | |
| LabCorp Transport Bags/with Pouch 6×9 in. | | Each | | Viral Multitransport | | Each | |
| Frozen Specimen Bags | | Each | | Blood Culture Bottles Adult ☐ Ped ☐ | | Each | \neg |
| Frozen Transport Tubes & Caps | | Each | | Swab, Transport - Pink/Red - Bacterial | | Each | |
| Sterile Container | | Each | | ProbeTec Swab | | Each | |
| | | | | LABELS | | | |
| DRUG SCREEN SUPPLIES | | | | Frozen Labels Small Red Large Blue | | Roll | |
| Drug Screen Cups, Lids (Single) | | Each | | Specimen I.D. Labels | | Roll | |
| NIDA/D.O.T. (Drug Screen Kits) (Double) | | Each | | AOE | | Roll | |
| | | | | | | | |
| | | T | | MISCELLANEOUS SUPPLIES | | | |
| TRANSPORT KITS | | | | Glucola (Orange Flavor) 50g 🔲 100g 🗍 | | Each | |
| Frozen Trans-Pak Bottles | | Each | <u> </u> | Glucola (Lemon-Lime Flavor) 50g 100g | | Each | |
| Fluid Transport Kit Amniotic | | Each | | Tourniquet | - | Each | |
| General Transport Kit | | Each | | | + | | |
| Taysachs Disease Kit | | Each | | | - | | |
| Bone Marrow Transport Kit | | Each | | OTHER | | | |
| Histology Special Studies | | Each | | Lockbox | | Each | |
| Cytology Special Studies | | Each | | | | | |
| | | | | | | | $\neg \neg$ |
| ime and Date Completed: | 1 | | | | 1 | | |

_____ Verified Order: _____

RPT# RCMB015-A

LABORATORY CORPORATION OF AMERICA HOLDINGS
STANDARD UTILIZATION REPORT

MANAGEMENT REPORTING SYSTEM

PAGE:

Date 09/07/2000

NDARD UTILIZATION REPORT

MANAGEMENT REPORTING SYSTEM
FINANCIAL DIV:

XXXXX

ADJ DOLLARS 1,192.30 5.00 12.00 9.00 18.003.00 349.10 500.25 32.67 93.36 56.00 0.00 90.81 54.54 38.50 21.91 176.96 19.79 22.70 2.03 24.60 95.10 33.40 26.00 3.35 18.00 17.40 35.00 77.60 378.00 21.32 16.40 439.65 1,160.30 10.51 YEAR-TO-DATE 102 9 SUB ACCT: ACCOUNT: 99999999 CURRENT MONTH DOLLARS 102.95 97.85 296.24 45.50 0.00 0.00 16.48 0.00 0.00 0.00 0.00 0.00 0.00 0.000.00 0.00 0.00 0.00 171.50 4.67 12.36 56.00 4.50 9.27 9.27 8.50 10.51 3.61 000000000000 QIY 6666 GROUP: 9.27 8.50 16.48 22.70 5.15 12.36 4.10 31.70 33.40 13.39 5.30 60.30 9.27 3.09 38.80 10.51 12.36 56.00 4.50 9.27 3.61 10.04 1.03 18.00 9.00 36.05 9.27 10.82 16.40 2.88 5.15 3.50 85.75 4.67 CHLAMYDIA TRACHOMATIS CULTURE GENTAMICIN, SERUM, PEAK/TROUGH BUN+CA+CREAT+K+NA+P+HGB+HCT CBC WITH DIFFERENTIAL/PLATELET CREATINE KINASE (CK). MB/TOTAL CHLAMYDIA/GC (CONFIRMATION) ANTINUCLEAR ANTIBODIES (ANA) CBC, NO DIFFERENTIAL/PLATELET PROSTATE-SPECIFIC AG, SERUM XXXXXXXXXXX ISH, HIGH SENSITIVITY, SERUM AEROBIC BACTERIAL CULTURE HEMOGLOBIN FRACTIONATION PHENYTOIN (DIANTIN), SERUM COMP. METABOLIC PANEL (13) INANCIAL REGION: XXXXXXXXX MICROSCOPIC EXAMINATION AFP, SERUM, TUMOR MARKER 88305 SURGICAL PATHOLOGY HELICOBACTER PYLORI, ICG BASIC METABOLIC PANEL (7) CREATININE, 24-HOUR URINE DIGOXIN (LANOXIN), SERUM CARBAMAZEPINE, SERUM HBV/HCV (PROFILE VIII) URINAL YSIS, COMPLETE VALPROIC ACID, SERUM HEP B SURFACE AB HEP B SURFACE AG HEMOGLOBIN A1C ANYLASE, SERUM GLUCOSE, SERUM CORTISOL - AM HEP C VIRUS AB TEST NUMBER AND NAME PANEL 083824 LIPID PANEL CMP12+8AC REGIONAL LAB: AST (SGOT) FOR AUGUST 2000 CEA303758 002139 310900 104018 255505 00500 339010 007419 717348 004259 001396 006254 001123 005017 64160 306510 008649 002311 03012 307385 301032 62289 001511 006072 083824 303756 883051 333328 003772 007260 002253 008565 01453 06395 40608 058867 007401 010322

HEP VII HIEP C

257113

| RPT# RCMB015-A STANDARD UTILI FINANCIAL D | RPT# RCMB015-A STANDARD UTILIZATION REPORT FINANCIAL DIV: | XXX | LABORATORY CORPORATION OF AMERICA HOLDINGS MANAGEMENT REPORTING SYSTEM | N OF AME ORTING S | RICA HOLDI YSTEM | NGS | Date 09/07/2000 | PAGE: 2 |
|---|---|--|---|----------------------|---------------------|-------------|------------------------------------|--------------|
| REGI | REGIONAL LAB: | XXXXXXXXX | GROUP: | 6666 | ACCOUNT: 99999999 | 66666666 | SUB ACCT: | |
| FOR AUGUST | IST 2000 QUANTIT | QUANTITIES OF TESTS ORDERED BY | STS ORDERED BY | | CXXXXXX 0 | CXX XXXXXXX | XXXX XXXXXXXXXXXX XXXXXXXX 6666666 | |
| | | | | CUR | CURRENT MONTH | H | YEAR-T | YEAR-TO-DATE |
| TEST NUMBI | TEST NUMBER AND NAME | | PRICE | QIY | DOLLARS | S | QTY AI | ADJ DOLLARS |
| 007336 TF | 007336 THEOPHYLLINE, | SERUM | 12.36 | 0 | 00.00 | | 4 | 48.00 |
| 000620 TF | THYROID PANEL WITH TSH | WITH TSH | 10.30 | 0 | 00.00 | | 'n | 50.00 |
| 001057 UF | AC ACID, SERI | JM | 2.06 | 0 | 0.00 | | 2 | 4.06 |
| 003038 UR | INALYSIS, RO | UTINE | 3.09 | 0 | 00.0 | | 34 | 102.09 |
| | INE CULTURE, | ROUTINE | 10.30 | 0 | 00.0 | | 2 | 20.60 |
| 717314 V | ANCOMYCIN, S. | ERUM, PEAK/TROUGH | 63.20 | 0 | 00.0 | | | 63.20 |
| 005025 WF | HITE BLOOD CE | WHITE BLOOD CELL (WBC) COUNT | 4.10 | 0 | 0.00 | | 2 | 8.20 |
| | | | | | | | | |
| *INDICATES | PRICE COULD | *INDICATES PRICE COULD NOT BE DETERMINED | | | | | | |
| | | | | | | | | |

6,301.94

914

861.57

86

*** ACCOUNT TOTAL

| DATE 10/04/2000 PAGE: | | ACCOUNT: 99999999 SUB ACCT: 99999999 | | 6 XXXX XXXXXX/XXXXX XXXX |
|--|-----------------------------|--------------------------------------|-------------------------|---|
| LABORATORY CORPORATION OF AMERICA HOLDINGS | PERSONAL MECONAING DISTRICT | GROUP: 9999 ACCOUNT: | | QUANTITIES OF TESTS ORDERED BY 99999999 XXXX XXXX |
| RPT# RCMB015-B | XXXXXXX | XXXXX | N: XXXXX | 00 |
| RPT# RCMB015-B | FINANCIAL DIV: | REGIONAL LAB: | FINANCIAL REGION: XXXXX | FOR SEPTEMBER 2000 |

| | | CURRENT MONTH | YEAR-TO-DATE |
|------------|--------------------------------|---------------|----------------|
| TEST NUMBE | TEST NUMBER AND NAME | QTY | QTY |
| 00200 | CBC WITH DIFFERENTIAL/PLATELET | . г | ঝ |
| 058867 | CMP12+8AC | н | Ŋ |
| 005199 | PROTHROMBIN TIME (PT) | П | 1 |
| 001149 | THYROXINE (T4) | н | 7 |
| 004259 | TSH, HIGH SENSITIVITY, SERUM | Н | 2 |
| 998085 | VENIPUNCTURE | Н | 4 |
| 162289 | HELICOBACTER PYLORI, IGG | 0 | 1 |
| 303756 | LIPID PANEL | 0 | г ч |

*** ACCOUNT TOTAL

LABORATORY CORPORATION OF AMERICA HOLDINGS MANAGEMENT REPORTING SYSTEM

RPT# RCMB015-C1
NATIONAL CMS UTILIZATION REPORT
TOTAL DIV:
TOTAL D

GROUP: 9999

ACCOUNT: 9999999

SUB ACCT:

| 6666 |
|---------------|
| XXX |
| XXXXXXXXX |
| 66666666 |
| |
| ΒY |
| TESTS ORDERED |
| TESTS |
| Q |
| QUANTITIES |

| | | | CURE | CURRENT MONTH | YEAF | YEAR-TO-DATE |
|----------|--------------------------------|-------|-------------|---------------|------|--------------|
| TEST NUM | TEST NUMBER AND NAME | H | QTY | DOLLARS | QTY | ADJ DOLLARS |
| 00200 | ٩ | 3.50 | 15 | 52.50 | 16 | 262.40 |
| 322758 | BASIC METABOLIC PANEL (8) | 7.30 | 7 | 51.10 | 19 | 138.70 |
| 303756 | LIPID PANEL | 6.18 | ιν | 30.90 | 30 | 183.24 |
| 322755 | HEPATIC FUNCTION PANEL (7) | ~ | 4 | 0. | 11 | 9 |
| 322000 | COMP. METABOLIC PANEL (14) | | ٣ | 15.75 | 16 | 4 |
| 333328 | MICROSCOPIC EXAMINATION | រហ | m | ы В. | 14 | 0 |
| 008557 | ENVIRONMENTAL CULTURE | 9.79 | 7 | ο, | 34 | 325.90 |
| 008482 | FUNGUS (MYCOLOGY) CULTURE | 12.62 | 7 | 25.24 | 9 | |
| 001032 | GLUCOSE, SERUM | ٥. | 2 | 6.18 | 4 | S |
| 235010 | LIPID PANEL WITH LDL/HDL RATIO | ĸ. | 7 | 30.60 | 19 | |
| 005199 | PROTHROMBIN TIME (PT) | 4 | 2 | 10.30 | ທ | 25.30 |
| 003772 | URINALYSIS, COMPLETE | 3.61 | 2 | 7.22 | 7 | ω. |
| 968100 | AMYLASE, SERUM | ۲. | | 5.15 | Q | 7. |
| 008169 | BETA-HEMOLYTIC STREP, A ONLY | ω. | Т | 12.36 | 1 | ω, |
| 008136 | FUNGUS STAIN | 22.00 | ~ | 22.00 | П | 22.00 |
| 162289 | HELICOBACTER PYLORI, IGG | 38.80 | Н | 38.80 | 1 | 38.80 |
| 322744 | HEPATITIS PANEL (4) | 89.90 | r+l | | н | 9. |
| 005249 | PLATELET COUNT | 2.06 | н | • | 73 | 4 |
| 001180 | POTASSIUM, SERUM | 2.06 | ц | 0 | ហ | 0 |
| 010322 | PROSTATE-SPECIFIC AG, SERUM | 9.27 | 1 | 9.27 | 2 | 18.54 |
| 162545 | QUANT, RNA PCR | ٥. | П | 95.00 | 27 | |
| 006072 | RPR | 3.55 | 1 | 3.55 | rd | 3.55 |
| 006197 | | | 1 | | Н | 6.64 |
| 160218 | RUBBOLA ANTIBODIES, IGM | r. | Н | 17.50 | rH | 17.50 |
| 005215 | SEDIMENTATION RATE-WESTERGREN | 3.09 | 1 | 3.09 | 71 | 60.9 |
| 050013 | SKIN LESION 1ST | ė. | 1 | 56.75 | 4 | 227.00 |
| 998823 | STAT CHARGE | ٥. | 1 | 35.00 | ц | 35.00 |
| 003038 | URINALYSIS, ROUTINE | 3.09 | ₽ | 3.09 | æ | 24.36 |
| 008649 | 밁 | 10.04 | o | | 12 | 118.16 |
| 303758 | BASIC METABOLIC PANEL (7) | 4.67 | 0 | 00.0 | 11 | 49.97 |
| 001040 | BUN | 2.06 | 0 | 00.0 | Н | 2.00 |
| 115907 | CBC/DIFFERENTIAL (NO PLATELET) | 6.30 | 0 | • | П | ų. |
| 005017 | | 4.10 | 0 | 00.00 | ٣ | 12.30 |
| 001065 | CHOLESTEROL, TOTAL | ĸ. | 0 | 00.00 | н | 2.00 |
| 027623 | CMP12+LP+6AC | 18.50 | 0 | 0.00 | 27 | 232.20 |
| 058867 | CMP12+8AC | 5.15 | 0 | 00.00 | 13 | 65.30 |
| 310900 | COMP. METABOLIC PANEL (13) | ń | 0 | 00.0 | 42 | 212.40 |
| 003004 | CREATININE CLEARANCE | 13.70 | 0 | 00.00 | H | 13.70 |
| 001370 | CREATININE, SERUM | 2.88 | 0 | 00.0 | 7 | 5.60 |
| 303754 | BLECTROLYTE PANEL | 4.12 | 0 | 00.00 | Н | 4.00 |
| 001917 | G-6-PD, QUANT, BLOOD AND RBC | 22.90 | 0 | 00.0 | m | 68.70 |
| 001958 | GGT | 8.30 | O | 00.00 | ಗ | 8.30 |
| | | | | | | |

_

LABORATORY CORPORATION OF AMERICA HOLDINGS MANAGEMENT REPORTING SYSTEM

QUANTITIES OF TESTS ORDERED BY XX999999 RPT# RCMB015-C1
NATIONAL CMS UTILIZATION REPORT FINANCIAL DIV: XXXXXXX REGIONAL LAB: XXXX FINANCIAL REGION: XXXX FOR SEPTEMBER 2000

ACCOUNT: XX999999 9999

GROUP:

SUB ACCT:

XX XXXXXXXX

| | ** | _ | _ | _ | - | | _ | _ | _ | _ | _ | | _ | _ | | _ | _ | ~ | _ | _ | _ | _ | _ | _ | _ | | _ | _ | _ | _ | _ | _ | _ | _ | _ | _ | |
|---------------|----------------------|------------------|----------------------|--------------------------------|---------------------|---------------------------|-----------------|---------------------|------------------|----------------------|-------------|---------|----------------------------|--------------------------------|------------------------------|---------------------|---------------------|-----------------|---------------------------------|--------------|---------------|--------------------------|----------------------------|-------------------------|---------|---------------------------|-------------------------|---------|-------------------------------|----------|--------------------------------|---------|---------------------|------------------------|--------------------------------|--------|------------------------|
| YEAR-TO-DATE | GROSS DOLLARS | 12,981.50 | 3,823.10 | 5,920.50 | 12,355.00 | 8,138.25 | 52 | ζ. | 817.50 | 240.00 | 4,360.60 | 434.25 | 484.80 | 322.00 | 191.25 | 776.00 | 2,708.90 | 2,944.68 | 1,400.00 | 420.00 | 128.00 | 108.00 | 66.00 | 96.80 | 30.00 | 73.25 | 63.50 | 16.80 | 309.00 | 37.00 | 128.50 | 11.00 | 67.20 | 2,356.50 | 210.00 | 12.00 | • |
| YEAR | QTY GR | 703 | 1,088 | 647 | 791 | 841 | 629 | 233 | 162 | 12 | 288 | 44 | 49 | 23 | 13 | 10 | 103 | 33 | 14 | 28 | ω | 6 | y | 8 | Ģ | rH | 러 | 4 | m | 67 | 14 | 7 | 2 | 252 | 24 | 4 | • |
| CURRENT MONTH | DOLLARS | 1,824.00 | 418.20 | 945.00 | 1,500.00 | 864.00 | 255.00 | 172.20 | 115.00 | 220.00 | 120.80 | 54.00 | 57.60 | 70.00 | 60.00 | 310.40 | 105.20 | 274.50 | 300.00 | 45.00 | 48.00 | 24.00 | 22.00 | 24.20 | 5.00 | 73.25 | 63.50 | 4.20 | 103.00 | 18.50 | 5.00 | 5.50 | 33.60 | 9.30 | 8.75 | 3.00 | |
| CURR | QTY | 160 | 123 | 105 | 100 | 96 | 51 | 42 | 23 | 11 | œ | 9 | 9 | ß | Ŋ | 4 | 4 | ო | m | m | M | 2 | 7 | 73 | ri | П | rel | r=i | П | П | П | Ħ | г | 1 | н | Н | , |
| | PRICE | 18.47 | 3.51 | 9.15 | 15.62 | 9.68 | 5.36 | 4.26 | 5.05 | 20.00 | 15.14 | 9.87 | 98.00 | 14.00 | 14.71 | 77.60 | 26.30 | 89.23 | 100.00 | 15.00 | 16.00 | α | 11.00 | 12.10 | 5.00 | 73.25 | 63.50 | 4.20 | 103.00 | 18.50 | 9.18 | 5.50 | 33.60 | 9.35 | 8.75 | 3.00 | |
| | TEST NUMBER AND NAME | CORONARY RISK II | COMPLETE BLOOD COUNT | HEMOGLOBIN A1c (GLYCOHEMOGLOBI | ULTRA-SENSITIVE TSH | PROSTATE SPECIFIC ANTIGEN | CHEMISTRY PANEL | URINALYSIS COMPLETE | PROTHROMBIN TIME | HEPATITIS C ANTIBODY | LIPID PANEL | DIGOXIN | HEPATIC FUNCTION PANEL (7) | HELICOBACTER PYLORI IGG ANTIBO | THEOPHYLLINE (AMINOPHYLLINE) | HEPATITIS PANEL (4) | THYROID + TSH PANEL | HEPATITIS PANEL | PSA TOTAL + % FREE (WITHOUT SM) | TESTOSTERONE | VALPROIC ACID | CARBAMAZEPINE (TEGRETOL) | PAP SMEAR-1 SLIDE(LC_MILL) | STOOL CULTURE (LC_MILL) | AMYLASE | ARTHRITIS PANEL W/O URINE | ARTHRITIS PNL W/O URINE | CALCIUM | CARBOHYDRATE AG 19-9 (LC_BUR) | CORTISOL | FERRITIN, SERUM (LC_SAN DIEGO) | FREE T4 | HAPTOGLOBIN (LC_BU) | HEPATIC FUNCTION PANEL | IRON AND IRON BINDING CAPACITY | LIPASE | THE CALL STREET STREET |
| | TEST NO | 1276 | 5020 | 2700 | 4027 | 4106 | 2000 | 5150 | 5100 | 4046 | 90066 | 4020 | 90729 | 6034 | 3030 | 90730 | 620 | 99005 | 90445 | 4062 | 2576 | 3075 | 00009 | 7014 | 2120 | 1017 | 90115 | 2080 | 45095 | 4042 | 90630 | 4023 | 1628 | 99002 | 2111 | 2231 | 7 7 0 1 7 |

* INDICATES PRICE COULD NOT BE DETERMINED

CONSOLIDATED GROUP TOTAL

787

8,225.30

7,150

76,814.80

LABORATORY CORPORATION OF AMERICA HOLDINGS MANAGEMENT REPORTING SYSTEM NATIONAL CMS UTILIZATION REPORT

RCMB015-C1

'n

DATE 10/10/2000 PAGE:

FINANCIAL REGION: XXXXXX XXXX XXXX XXXXX XXXXXXX FINANCIAL DIV: REGIONAL LAB:

SUB ACCT: ACCOUNT: 99999999 GROUP: 9999

YEAR-TO-DATE QUANTITIES OF TESTS ORDERED BY 9999999 XXXXXXXXXX XXX 9999 00.0 0.00 0.00 00.0 0.00 0.00 00.0 00.00 0.00 00.0 0.00 00.0 00.0 00.0 0.00 0.00 00.0 0.00 0.00 0.00 0.00 00.0 00.0 DOLLARS CURRENT MONTH 000000000000000000000 7-KETOGENIC STEROIDS, 24-H UR VANILLYIMANDELIC ACID, 24-HR U VARICELLA ZOSTER ABS, IGG/IGM VARICELLA-ZOSTER VIRUS CULTURE VIRAL CULTURE, INFLUENZA VIRUS VIRAL HEPATITIS PROFILE-IMUNE VITAMIN B1 (THIAMINE), BLOOD VITAMIN B12 (TRUE COBALAMIN) VIT D 1,25 DIHYDROXY (LC_BU) Vitamin D, 25-Hydroxy VALPROIC ACID, FREE, SERUM 5-HIAA, UR-QUANT (LC BUR) 5-HIAA, QUANT., 24 HR URINE VITAMIN D, 1,25 DIHYDROXY 88302 SURGICAL PATHOLOGY WET PREP (LC_VEGAS)
WOUND CULTURE (LC_MICRO) 88304 SURGICAL PATHOLOGY 88305 SURGICAL PATHOLOGY VITAMIN E1, SERUM (LC_BU) WET MOUNT FOR PARASITES VIRAL CULTURE, GENERAL ZONE 1 TRANSPORT FEE 071175 7 DRUG-UNB 788281 7 DRUG-BUND 770628 7 DRUG-SCR 074021 9 DRUG-SCR 788471 9+ALC-BUND VITAMIN E, SERUM VOLATILES, BLOOD 5' NUCLEOTIDASE VITAMIN A & E VENT PUNCTURE ZINC, SERUM ZINC, URINE VIRAL PANEL VITAMIN KL VITAMIN B6 TEST NUMBER AND NAME FOR SEPTEMBER 2000 081000 007062 071175 004010 004069 770628 081950 070789 004143 998085 028910 227492 144006 121186 004655 808535 008599 001800 003434 074021 001701 788281 788471 883021 883042 883053 235945 081091 008243 008573 008102 099101 81000 54072 81091 4069 4051 7013

INDICATES PRICE COULD NOT BE DETERMINED

*

CONSOLIDATED GROUP TOTAL

322,088.31 25,592

245,597

RPT# RCMB015-C1
NATIONAL CMS UTILIZATION REPORT
FINANCIAL DIV: XXXXXXXX
REGIONAL LAB: XXXXXXX XXXX
FINANCIAL REGION: XXXXXX XXXX
FOR SEPTEMBER 2000

LABORATORY CORPORATION OF AMERICA HOLDINGS MANAGEMENT REPORTING SYSTEM

ACCOUNT: 9999999

SUB ACCT:

GROUP: 9999

QUANTITIES OF TESTS ORDERED BY 9999999 XXXXXXXXXXX XXX 9999

TEST NUMBER AND NAME

DOLLARS CURRENT MONTH ÕΙΧ

YEAR-TO-DATE QTY DOLLARS

245,597 2,868,619.18

25,592

CONSOLIDATED GROUP GRAND TOTAL

322,088.31

DATE 10/10/2000 PAGE: 4

| Г÷ | |
|--------------|---|
| C | ١ |
| C | • |
| _ | |
| 2 | į |
| C |) |
| <u> </u> | ı |
| ٦ | |
| ◪ | ١ |
| \sim | , |
| <u> </u> | ۱ |
| č | , |
| т. | 1 |
| P | í |
| C | Ì |
| \mathbf{c} | Ì |
| _ | |
| ` | |
| ~ | , |
| 进 | |
| Ō | ' |
| | |
| A | i |
| α | |
| 0 | |
| BO | |
| A | |
| | |
| Н | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

DATE 10/04/2000 PAGE: QUANTITIES OF TESTS ORDERED BY 9999999 XXXXX XXXXXXXXXXXXXX SUB ACCT: AMERICA HOLDINGS ACCOUNT: 9999999 MANAGEMENT REPORTING SYSTEM 6666 GROUP: PHYSICIAN LEVEL UTILIZATION REPORT FINANCIAL DIV: XXXXX REGIONAL LAB: XXXXXXXXXXX FINANCIAL REGION: XXXXXXXXXX FOR SEPTEMBER 2000 RPT# RCMB015-D

| DATE | | | | CURREN | CURRENT MONTH | YEAR-TO- |
|---|---------|--------------------------------|-------|--------|---------------|----------|
| ORDERING PHYSICIAN DOLLARS | TEST NU | TEST NUMBER AND NAME | PRICE | QTY | DOLLARS | QTY ADJ |
| 0.00 | 333328 | MICROSCOPIC EXAMINATION | 4.50 | 113 | 508.50 | 905 |
| NON-FORMULARY TOTAL 0.00 | | | | 113 | 508.50 | 905 |
| PHYSICIAN TOFAL | | | | 113 | 508.50 | 908 |
| 2.235.20 | 058867 | CMP12+8AC | 5.15 | 118 | 607.70 | 505 |
| 1 317 20 | 00200 | CBC WITH DIFFERENTIAL/PLATELET | 3.50 | 59 | 206.50 | 382 |
| 20 CA | 008649 | AEROBIC BACTERIAL CULTURE | 10.04 | 14 | 140.56 | 54 |
| 0.41 | 007708 | LITHIUM (ESKALITH), SERUM | 7.21 | 73 | 14.42 | 77 |
| 243 00 | 008847 | URINE CULTURE, ROUTINE | 10.30 | 7 | 20.60 | 24 |
| 48.30 | 006072 | RPR | 3.55 | 0 | 0.00 | 14 |
| FORMULARY TOTAL 4,528.29 | | | | 195 | 989.78 | 1,000 |
| ¢+ £¢+ | 008300 | BLOOD CULTURE, ROUTINE | 8.24 | æ | 65.92 | 15 |
| 178 40 | 200003 | SENSITIVITY ORGANISM #1 | 5.20 | 80 | 41.60 | 45 |
| 2 | 070466 | CHAIN-OF-CUSTODY PROTOCOL | 3.50 | 7 | 24.50 | 53 |
| 09.92 | 001859 | CK+LDH ISO | 38.30 | гi | 38.30 | 73 |

| 00 91 | 003442 | OSMOLALITY, URINE | 16.00 | н | 16.00 | а |
|-------------------------------|--------|------------------------------|-------|-----|----------|--------|
| 10.40 | 800003 | SENSITIVITY ORGANISM #3 | 5.20 | н | 5.20 | N |
| 0 US. | 301110 | BUN+CA+CO2+CREAT+K+NA+P+URI | 8.60 | 0 | 00.00 | ri. |
| 00.9 | 001115 | ноп | 6.30 | 0 | 00.0 | ч |
| 79.25 | 480640 | PSA TOTAL (REFLEX TO FREE) | 79.25 | 0 | 00.0 | ч |
| 5.15 | 003541 | UREA NITROGEN, 24-HOUR URINE | 5.15 | 0 | 0.00 | Н |
| NON-FORMULARY TOTAL 689.02 | | | | 26 | 191.52 | 122 |
| PHYSICIAN TOTAL 5,217.31 | | | | 221 | 1,181.30 | 1,122 |
| BATES 7,558.08 | 083824 | PANEL 083824 | 12.88 | 47 | 605.36 | 592 |
| FORMULARY TOTAL 7,558.08 | | | | 47 | 605.36 | 592 |
| PHYSICIAN TOTAL 7,558.08 | | | | 47 | 605.36 | 592 |
| BELL 159.60 | 001149 | THYROXINE (T4) | 8.40 | 0 | 0.00 | Н 6 |
| NON-FORMULARY TOTAL 159.60 | | | | 0 | 00.00 | 1.9 |
| PHYSICIAN TOTAL | | | | 0 | 0.00 | 19 |

| DATE 10/04/2000 PAGE: | | SUB ACCT: | XXXXX XXXXXXXXXXX |
|--|--|--|-----------------------------------|
| OLDINGS | . | ACCOUNT: 99999999 | X XXXXX 6666 |
| MERICA H | G SYSTEM | ACCOUN | 66666 |
| PORATION OF A | MANAGEMENT REPORTING SYSTEM | 6666 | TIES OF TESTS ORDERED BY 99999999 |
| LABORATORY CORPORATION OF AMERICA HOLDINGS | MANAGEN | GROUP: | QUANTITIES OF TEST |
| | PHYSICIAN LEVEL UTILIZATION REPORT INANCIAL DIV: | XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX | 00 |
| RPT# RCMB015-D | PHYSICIAN LEVEL UFINANCIAL DIV: | REGIONAL LAB: XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX | FOR SEPTEMBER 2000 |

| e e e e e e e e e e e e e e e e e e e | | | CURRE | CURRENT MONTH | YEAR-TO- |
|--|---|-------|-------------|---------------|-------------|
| ORDERING PHYSICIAN | TEST NUMBER AND NAME | PRICE | QTY | DOLLARS | QTY ADJ |
| TINGLEY 1,815.00 | 163550 PANEL 163550 82 | 82.50 | н | 82.50 | 22 |
| NON-FORMULARY TOTAL 1,815.00 | | | н | 82.50 | 22 |
| PHYSICIAN TOTAL | | | Н | 82.50 | 22 |
| WEST 60.25 | 883121 SPEC-STAIN, GRP I-MICRO 1ST | 39.00 | 0 | 00.00 | Ø |
| NOM-FORMULARY TOTAL 60.25 | | | 0 | 00.0 | 7 |
| PHYSICIAN TOTAL 60.25 | | | 0 | 00.0 | 7 |
| * INDICATES PRICE CO | INDICATES PRICE COULD NOT BE DETERMINED | | | | |
| *** ACCOUNT TOTAL 36,920.25 | | | 718 | 5,874.66 | 5,010 |
| FORMULARY ACCOUNT TOTAL 15,441.67 | TOTAL | | 281 | 2,134.45 | 1,886 |
| PERCENTAGES | VTAGES | | ც ტ % | | % & & |
| NON-FORMULARY ACCOUNT TOTAL 21,478.58 | TOTAL | | 437 | 3,740.21 | 3,124 |

RPT# RCMB015-E

LABORATORY CORPORATION OF AMERICA HOLDINGS

PHYSICIAN LEVEL UTILIZATION REPORT

OTY ADJ DOLLARS DATE 10/18/2000 PAGE: 1 89 12 21 23 23 27 14.52 20.07 66.42 16.92 0.00 8.38 11.26 10.88 69.9 6.50 0.00 0.00 0.00 0.00 22.75 115.50 9.21 43.38 25.14 8.14 5.30 DOLLARS 56.49 SUB ACCT: 42 ACCOUNT: 9999999 10.88 4.19 5.30 69.9 6.50 8.07 4.38 5.66 13.94 3.25 16.50 8.07 11.07 2.82 3.63 3.07 21.69 5.63 12.57 4.07 .21.50 PRICE MANAGEMENT REPORTING SYSTEM CBC/DIFFERENTIAL (NO PLATELET) CBC, NO DIFFERENTIAL/PLATELET TSH, HIGH SENSITIVITY, SERUM AFB CULTURE AND SMEAR, BROTH PHENYTOIN (DILANTIN), SERUM COMP. METABOLIC PANEL (14) LITHIUM (ESKALITH), SERUM AEROBIC BACTERIAL CULTURE MICROSCOPIC EXAMINATION SENSITIVITY ORGANISM #1 URINE CULTURE, ROUTINE BLOOD CULTURE, ROUTINE BASIC METABOLIC PANEL GROUP: URINALYSIS, COMPLETE CARBAMAZEPINE, SERUM ROUTINE RETICULOCYTE COUNT ELECTROLYTE PANEL FERRITIN, SERUM HEMOGLOBIN ALC ALBUMIN, SERUM IRON AND TIBC VENIPUNCTURE TEST NUMBER AND NAME URINALYSIS, LIPID PANEL PT AND PTT TRAVEL YEAR-TO-DATE STAT FINANCIAL REGION: XXXXXXXX XXXXXX 005280 998085 004598 303754 001453 008649 303758 008300 960866 04259 322000 333328 003038 007419 115907 007708 182402 001081 005017 008847 303756 998074 003772 001321 020321 007403 500001 XXXXXXXX REGIONAL LAB: XXXXXXX ORDERING PHYSICIAN FOR SEPTEMBER 2000 FINANCIAL DIV: CURRENT MONTH

80.97

89.11

1.87CR 145.45

90.63

340.68

65.87 37.24 7.44

224.27

123.30

1,500.44 343.55 191.58 0.00

1,044.71 547.42 65.16

250.93

32.61

65.44CR

31.58

290.35 80.69 52.21

333,98

8,253.99

1,391

638.05

140

8.07

COMP. METABOLIC PANEL (13)

310900

386181

C DIFFICILE TOXIN A

GENITAL CULTURE, ROUTINE

GLUCOSE, SERUM

001032

18,68

PHYSICIAN TOTAL

LABORATORY CORPORATION OF AMERICA HOLDINGS PHYSICIAN LEVEL UTILIZATION REPORT RPT# RCMB015-E

DATE 10/18/2000 PAGE: 1 SUB ACCT: ACCOUNT: 99999999 MANAGEMENT REPORTING SYSTEM GROUP: FINANCIAL REGION: XXXXXXX XXXXXX XXXXXXXX REGIONAL LAB: XXXXXXX FOR SEPTEMBER 2000 FINANCIAL DIV:

11.50 8.10 8.10 61.50 17.10 78.60 11.48 59.40 59.40 11.50 363.75 145.00 11.48 QTY ADJ DOLLARS 195.75 2 5 7 7 2 2 QUANTITIES OF TESTS ORDERED BY 9999999 XXXXXXXXX XXXXXXXX XXXXXXXX 8.10 0.00 0.00 0.00 0.00 00.0 00.00 8.10 61.50 17.10 78.60 DOLLARS 195.75 0001 0 0 00 $-\infty$ 29.70 11.50 11.50 72.50 61.50 17.10 8.10 PRICE 195.75 11.48 STRIATIONAL ANTIBODIES FO81 CHEESE, CHEDDAR HEP B CORE AB, IGM 006890 BACTERIAL ANTIGENS LORAZEPAM (ATIVAN) RAST FOOD PROFILE ALLERGENS, ZONE 3 TRAZODONE, SERUM TEST NUMBER AND NAME F025 TOMATO * INDICATES PRICE COULD NOT BE DETERMINED YEAR-TO-DATE 676536 068122 660423 224512 071688 016881 061507 160184 PHYSICIAN TOTAL PHYSICIAN TOTAL PHYSICIAN TOTAL TOTAL PHYSICIAN TOTAL ORDERING PHYSICIAN PHYSICIAN CURRENT MONTH WILLS/HEID ZHOU/NEWTO WAKSTEIN WAKSTEIN WAKSTEIN WAKSTEIN ZHOU ZHOU 1000

114,942.57

4,954

12,289.24

554

*** ACCOUNT TOTAL

Rpt #RCMB015-F CONSOLIDATED GROUP REPORT GROUP: 9999

3/22/2001 LABORATORY CORPORATION OF AMERICA HOLDINGS MANAGEMENT REPORTING SYSTEM

PAGE 1

| GRUUP: 9999 FOR FEBURARY 2001 | QUANTITIES OF TESTS ORDERED BY: 9999999 | XXXXX | XXXXXXXX XXX XXXXXXXXX | XXXXX | |
|---|---|-----------------|------------------------------|-----------------|--------------------------------|
| | AVERAGED PRICE | CURRI | CURRENT MONTH YTY DOLLARS | YEAR-1 QTY A | YEAR.TO-DATE TY ADJ DOLLARS |
| 1EST NUMBER AND NAME 058867 CMP12+8AC | 5.15 | 130 | 05.999 | 747 | 1 272 05 |
| 005009 CBC WITH DIFFERENTIAL/PLATELET | 3.50 | 69 | 241.50 | 187 | 654.50 |
| 107177 EP+15AC+PREBUN+PSTBUN | 51.50 | 32 | 1,648.00 | 63 | 3,244.50 |
| 004598 FERRITIN, SERUM | 5.15 | 32 | 164.80 | 62 | 319.30 |
| 339010 IRON AND TIBC | 9.01 | 32 | 288.32 | 63 | 567.63 |
| | 10.51 | | 315.30 | 61 | 641.11 |
| | 3.55 | 52 5 | 81.65 | 110 | 390.50 |
| | 40.00 2 O.S | 71 | 32.06 | 97 70 | 1,040.00 |
| | 49.50 | 3 5 | 32.30 643.50 | 25 13 | 643.50 |
| | 15.45 | 17 | 185.40 | 14 | 216.30 |
| | 3.55 | 12 | 42.60 | 12 | 42.60 |
| | 7.30 | 11 | 80.30 | 23 | 167.90 |
| 600401 PHENYTOIN (DILANTIN), SERUM | 9.27 | ∞ ∘ | 74.16 | 41 | 129.78 |
| | 0.2.0 | ×οr | 41.60 | 81 . | 93.60 |
| | 6.50 5.15 | ~ vc | 30.90 | 20 | 103.00 |
| | 9.27 | 'n | 46.35 | 6 | 83.43 |
| | 8.24 | · vo | 41.20 | 7 | 57.68 |
| | 5.20 | VΊ | 26.00 | 5 | 26.00 |
| | 10.04 | ᢦ . | 40.16 | ∞ ' | 80.32 |
| 180810 LOWEK KESPIKATOKY CULTUKE | 12.50 | ₫ • | 50.00 | φ, | 75.00 |
| 000520 TRYROLD APNEL WITH 1SH 003038 TRINAI VSIS ROTTMIR | 10.30 | 4 4 | 41.20 | 9 01 | 61.80 |
| | 5.03 | † (1 | 10.30 | 10 | 30.90 |
| | 4.50 | י אי | 13.50 | n v | 25.81 0.00 |
| | 9.27 | ייי ו | 27.81 | 9 | 55.62 |
| | 5 | m | 159.60 | 4 | 212.80 |
| | | ო | 9.27 | 7 | 21.63 |
| | 10.30 | m i | 30.90 | 1 | 8185.40 |
| 883031 88303 SUKGICAL PATHLUGY | 57.58 | n e | 257.25 | | 600.25 |
| 001550 AMILASE, SEKUM 303758 BASIC METABOLIC PANEL (7) | 5.15 | 7 (| 10.30 | u | 15.45 |
| | /O't+ 0 1 0 | 4 C | 9.54 8.20 | J C | 14.01 2.20 |
| | 5.40 | 1 C | 10.80 | 1 KA | 16.20 |
| | 9.70 | 7 | 19.40 | 5 | 19.40 |
| | 13.70 | 7 | 27.40 | 4 | 54.80 |
| | 6.18 | 7 | 12.36 | 3 | 18.54 |
| | 18.00 | 7 | 36.00 | 2 | 36.00 |
| | 11.33 | 7 ' | 22.66 | 4 (| 45.32 |
| 883121 SFEC-SIAIN, GRF I-MICKO I | 18.00 | 7 (| 78.00 | <i>ა</i>) (| 117.00 |
| | 12.30 | 4 C | 37 96 | 7 6 | 24.72 |
| | 04.01 | 1 - | 20.00 | 2 ر | 1 1 70 00 |
| VIDTO ALCIMINOM, SENOM | | ⊣ | 38.00 | 16 | 1,1/8.00 |
| *INDICATES PRICE COULD NOT BE DETERMINED |) *** CONSOLIDATED GROTE TOTAL | 535 | 50 5859 | 1139 | 12 758 92 |
| | CONSCIENT OF THE CONTRACTOR AND THE | 1 | 20.000 | 7011 | 14,100.74 |
| | | | | | |

LABORAIORY CORPORATION OF AMERICA HOLOTHGS MANAGEMENT REPORTING SYSTEM

ACCOUNT: 12853552

SUB ACCI:

DATE 05/03/2002 PAGE:

VESE-PA-ABPE

QUANTITIES OF TESTS ORDERED BY : 12053552 MARSHALL BROWNING HOSPITAL

CTADUP:

| | | YE | AR-IO-DAIE |
|-----------|--------------------------------|-----|------------|
| iesi muko | ESAN OVA AES | QIY | COLLARS |
| 004598 | Perrifin. Serum | 20 | 397.45 |
| 550392 | HCV RMA, QUAMI (QUAM REFLEX) | 20 | 4.057.70 |
| 001321 | IRC DAIL DAA TORC | 16 | 211.86 |
| 002253 | APP, SERUM, TUMOR MARKER | 12 | 388.52 |
| 006254 | ANTÍNUCLEAR ANTIRODIES (ANA) | 12 | 348.75 |
| 006643 | ANTISMOOTH MUSCIE AB, QUANT | 12 | 302 27 |
| 550405 | HCU RNA BY PCR | 11 | 1.170.80 |
| 550475 | HEPATITIS C VIRUS GEWOTYPING | 11 | 3,240.69 |
| 095653 | 4YIOWENS WISSYNTING-1-AHSIA | 9 | 383 85 |
| 006650 | AVIIKIIOCHOVORIAI AE (AKA). QV | 9 | 199.83 |
| 006726 | HEP A AR, ICIAL | 9 | 225 78 |
| 006310 | HEP B SURFACE AC | 9 | 141 78 |
| 140602 | HEP C VIRUS AB | 2 | 190 53 |
| 550111 | HCV AWA, PCR, QUANTITATIVE | 6 | 1.004 99 |
| 004937 | TRANSPERRIN | 6 | 158 67 |
| 006395 | HEP E SURPACE AB | 5 | 150 16 |
| 000210 | VITAMIN B12 AND POLATE | 4 | 141 60 |
| 164111 | CELIAC DISEASE AR PROFILE | 3 | 237.27 |
| 001404 | LIPASE, SERUM | 3 | 22 41 |
| 140277 | ERYTHROPOIETIN (EPO), SERUM | 2 | 51 94 |
| 006619 | HEP BE RG | 2 | 31 34 |
| 002030 | ALDOLASE | 1 | 13 42 |
| 001982 | AIPHA-1-AWIITRYPSIW. SERUM | 1 | 5 45 |
| 004895 | CALCITONIN. SERUM | 1 | 34 26 |
| 002261 | CAREGHYDRATE ANICEN 19-9 | 1 | 28 76 |
| 001529 | CAROTEME. BETA | 1 | 12 75 |
| 001560 | CERULO PLÁSMIM | 1 | 72 62 |
| 706556 | CYCLOSPORIUE, BLOOD | 1 | 162 00 |
| 002014 | FOLATES (FOLIC ACID), SERUM | 1 | 15 32 |
| 004390 | Castain, serum | 1 | 17 25 |
| 001958 | GGT | 1 | 7 50 |
| 550033 | HCV QUANTASURE PLUS (SERIAL) | 1 | 121 72 |
| 220400 | HCV RYA, PCR, QUALITATIVE | 1 | -116 41 |
| 501453 | HENDCLOBIN Alc | 1 | 13 42 |
| 806718 | HEP & CORE AR. TOT | 1 | 23 72 |
| 006635 | HEP RE AR | 1 | 15 92 |
| 163980 | LIVER-KIBHEY MICROSOMAL AB | 1 | -62 23 |
| 010322 | PROSTATE-SPECIFIC AG, SERUM | 1 | 25.42 |
| 012005 | RPR, RPX QN RER/CONFIRM IP-PA | 1 | 12 60 |
| 706242 | IACROLIMUS (PX506), RLOOD | 1 | 18 57 |
| 001974 | INYROXIVE (14) PREE, DIRECT, S | 1 | 12 46 |
| 010389 | IRIIODOIHYRONINE, FREE, SERUM | 1 | 23 41 |
| | | | |

Reis Acmedia-C IABORATORY CORPORATION OF AMERICA HOLDINGS DATE 05/03/2002 PAGE: 2
FINANCIAL DIV: CENTRAL
REGIONAL LAB: LOUISVILLE GROUP: ACCOUNT: 12053552 SUB ACCI:
FINANCIAL REGION: LOUISVILLE
FOR APRIL 2007 GUANTITIES OF IESIS ORDERED BY: 12053553 MARSHALL EROWNING HOSPITAL

YEAR-IO-DATE

| TEST NUMBER AND NAME
| STATE | TOTAL | TOTAL

DAIR 05/03/2002 PAGE:

epriolich abertak to noibroprod yrotrobei Manazement reporting eyetek Leri 2002

RFIS ACREDIT-H
SIRVARRA UTILIZATION LIME OF BUSINESS
FINANCIAI BIV : NORTHEAST
REGIONAL LAE : RARITAM
FINANCIAL REGION: DELEWARE REGION
ACCOUNT: 07102390 MIOBLETOWN PUBLIC REALIN

| IBSI MUMI | BEA AUG UAME | CONSTRUCTOR | CUF QTY | HIKOM IKERI SALIDO | gry | STAG-OT-RASY STAILOG LGA |
|-----------|--------------------------------|-------------------------|-------------|-------------------------------|--------------------|-----------------------------------|
| 005235 | ALB+ALP+ALI+ASI+BUW+CA+CHOI | 060 PI IAIOIAI | 0 0 0 | 0 00 0 00 | 0 0 | 36.70 ~14.00 22.70 |
| 181202 | AMTICARBIOLIPIN AB, 102/1026 | CM TOTAL | 0 0 | 9 00 9 00 | 3 | 240.00 240.00 |
| 162322 | AMPINEUIROPHI CHIOPINEUENIC AE | CM IOTAI | វ ០ | 0 00 0 0 | 2 | 302.00 302.00 |
| 006234 | AMILUUCIEAR AMILEODIES (AMA) | CM | 0 0 | 0 00 0 00 | 4 4 | 120.00 120.00 |
| 007187 | CARBON MONDXIDE, BLOOD | IS INTOI | 2 | 60.00 | 2 | 23.84 23.84 |
| 003009 | CBC WITH DIFFERENTIAL/PLATELET | CM NG PI IOIAI | 2 2 4 | 9.60 0.00 9.60 19.20 | 16 0 2 12 | 67.96 17.16 -12.52 72.60 |
| 310980 | COMP. METABOLIC PAMEL (13) | CM MO PI TOTAL | 0 0 0 | 0 00 0 00 0 00 | 4 0 0 4 | 36.00 10.70 -14.94 31.76 |
| 322000 | COMP METABOLIC PAMEL (14) | I9 Laïor | 0 | 0 00 | D D | -9 36 -9.36 |
| 038480 | H.I DKA HEY | PI TOTRI | 4 | 237 52 237 52 | 4 | 169 98 169 98 |
| 001032 | CIUCOSE, SERUM | MD 19 14101 | 6 2 3 | 32 80 8 20 24 60 | 58 \$ 54 | 98 40 17 46 115.86 |
| 192005 | GYMECOLOGIC MOMO-LAYEN PAP | CM IOIAI | D | 0 00 0 00 | 2 2 | 77.50 77.50 |
| 004416 | RCG. BEIN SUBUNII. QNI, SENUM | cm To tal | D D | 0 09 0 . 09 | 2 | 80.00 80.00 |

RPIS RCMB015-H LA SIRMBARD UTILISATION LINE OF EUSINESS FINANCIAL DIV : NORTHEAST REGIONAL LAB : RARIIAN FINANCIAL REGION: DELAWARE REGION ACCOUNT: 07108990 MIDDIETOWN PUBLIC HEALTH

LABORATORY CORPORATION OF AMERICA HOLDINGS MANAGEMENT REPORTING SYSTEM APRIL 2002

152.00 339.42 2,909.04 0.00 3,900.46

DATE 05/03/2802 PACE:

77.60 1,262.96 11,476.46 116.00 12,939.02

12 94 666

TOTAL ACCOUNT

CURRENT MONTH
GIV 0011ARS MIRG-OI-RABY RRAILOG LOA YIG iesi number and name COMPANY CODE CM PI IGIAI 411 10 122 40 533 50 2 4 12 148 B0 74 B0 222 B0 24 BBBBBB THYROID PAMEI WITH TSH 6 30 004259 0 0.00 0.00 -17 16 -17 16 ISH PI INTAL 003038 URINALYSIS, ROUTINE MO MICIAI 0 0.00 25 20 25 20 0 .00 992025 VEHIPUNCTURE PI TOTAL 0 0 -1 45 -1 46 122.00 122.00 376 00 376 00 CM IOIAL 283051 32305 SURG PAIN-1ST SITE

MO PI CK PI IOIAI

DATE 08/08/2002 PAGE:

IABORATORY CORPORATION OF AMERICA HOLDINGS MANAGEMENT REPORTING SYSTEM JULY 2002

| IEST NUM | BER AND NAME | COMPANY CODE | QIY (| CURRENT MONTH DOLLARS | QTY | YEAR-IO-DATE ADJ DOLLARS |
|----------|--------------------------|-------------------------------------|---|---|-------------------------------------|--|
| 883054 | 88305 SURG PATH-41H SITE | CM PI IOTAL | 3 1 4 | 181.50 60.50 242 00 | 14 1 15 | 71 27 41 60 112 87 |
| 883055 | 88305 SURG PATH-5TH SITE | CM PI TOTAL | 2 1 3 | 121 00 60 50 181 50 | 4 1 5 | 19.93 41 60 61 53 |
| 883056 | 88305 SURG PATH-6TH SITE | CM PI IOTAL | 1 1 2 | 60.50 60.50 121.00 | 1 1 2 | 6 38 41 60 47 98 |
| 883057 | 88305 SURG PATH-7TH SITE | PI TOIAI | 1 | 60 50 60 50 | 1 | 41 60 41 60 |
| 883071 | 88307 SURGICAL PATHOLOGY | CM PI IOTAL | 0 0 0 | 0.00 0.00 0.00 | 3 1 4 | 23 98 137 60 161 58 |
| Т83311 | 88331 TECH COMP-1ST SITE | PT TOIAL | 1 | 43 25 43 25 | 1 1 | 23 85 23 85 |
| 183321 | 88332 TECH COMP-1ST SIIE | PT TOTAL | 1 1 | 21 50 21 50 | 1 1 | 12.24 12.24 |
| 183322 | 88332 TECH COMP-2ND SITE | PT TOIAI | 1 1 | 21 50 21.50 | 1 1 | 12 24 12 24 |
| 183323 | 88332 FECH COMP-3RD SITE | PT TOTAL | 1 1 | 21.50 21.50 | 1 1 | 12 24 12 24 |
| 183324 | 88332 IECH COMP-41H SITE | PI TOTAL | 1 | 21.50 21.50 | 1 1 | 12 24 12 24 |
| 183325 | 88332 TECH COMP-STH SITE | PT IOIAI | 1 | 21 50 21 50 | 1 1 | 12 24 12 24 |
| | FOIAI ACCOUNT | CM MC PI PT MD TOIAL | 4,136 310 577 20 3 5,046 | 110,375.48 17,236.30 20,276.22 2,478.75 48.14 150,414.89 | 17,063 1,548 2,414 58 3 | 43,033 47 34,253 33 27,011.52 5,452 40 22 89 109,773 61 |
| T83321 | 88332 TECH COMP-1ST SITE | PT TOTAL | 1 | 21.50 21.50 | 1 1 | 12 24 12 24 |
| T83322 | 88332 TECH COMP-2ND SITE | PT TOTAL | 1 1 | 21.50 21.50 | 1 1 | 12 24 12 24 |
| ТВЗЗ2З | 88332 TECH COMP-3RD SITE | PT TOTAL | 1 1 | 21 50 21 50 | 1 | 12.24 12.24 |
| Т83324 | 88332 TECH COMP-4TH SITE | PT TOTAL | 1 1 | 21 50 21 50 | 1 | 12 24 12 24 |
| т83325 | 88332 TECH COMP-5TH SITE | PT TOTAL | 1 1 | 21.50 21.50 | 1 1 | 12 24 12 24 |